Pulmonary manifestations during neutrophil engraftment in recipients of allogeneic hematopoietic cell transplantation for myelofibrosis

Pulmonary manifestations during neutrophil engraftment in recipients of allogeneic hematopoietic cell transplantation for myelofibrosis | Research Square window.SnipcartSettings = { analytics: { enabled: false } }; (function() { var accessVector = localStorage.getItem('access_vector') || ''; window.dataLayer = window.dataLayer || []; if (accessVector) { window.dataLayer.push({ user: { profile: { profileInfo: { snid: accessVector } } } }); } })(); (function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src='https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);})(window,document,'script','dataLayer','GTM-K279D39R'); Browse Preprints In Review Journals COVID-19 Preprints AJE Video Bytes Research Tools Research Promotion AJE Professional Editing AJE Rubriq About Preprint Platform In Review Editorial Policies Our Team Advisory Board Help Center Sign In Submit a Preprint Cite Share Download PDF Article Pulmonary manifestations during neutrophil engraftment in recipients of allogeneic hematopoietic cell transplantation for myelofibrosis Vinod Pullarkat, Salman Otoukesh, Idoroenyi Amanam, Dongyun Yang, and 15 more This is a preprint; it has not been peer reviewed by a journal. https://doi.org/ 10.21203/rs.3.rs-6568124/v1 This work is licensed under a CC BY 4.0 License Status: Published Journal Publication published 24 Sep, 2025 Read the published version in Bone Marrow Transplantation → Version 1 posted 10 You are reading this latest preprint version Abstract Allogeneic hematopoietic cell transplantation (alloHCT) remains the only potentially curative treatment for both primary and secondary myelofibrosis (MF). However, outcomes are often complicated by the presence of cardiopulmonary comorbidities common in this patient population, contributing to elevated non-relapse mortality (NRM). In this study, we characterize a distinct clinical entity—pulmonary manifestations during neutrophil engraftment—marked by pulmonary infiltrates and respiratory compromise in patients undergoing alloHCT for MF. Eighteen of 83 patients (22%) developed these pulmonary complications, with radiologic findings including ground-glass opacities, consolidations, and pulmonary nodules. Notably, only one-third of these patients exhibited additional features typically associated with classical engraftment syndrome. Pulmonary arterial hypertension (PAH) was significantly associated with the development of these complications (odds ratio 3.68; 95% CI: 1.13–12; P = 0.04), whereas no correlation was found with pre-transplant pulmonary function testing or imaging. Hypoxemia was observed in 15 of the 18 affected patients. Despite the severity—44% requiring intensive care and 40% necessitating mechanical ventilation—all patients responded favorably to corticosteroids and supportive care. Importantly, the presence of pulmonary complications during engraftment did not negatively affect overall survival or NRM. Biological sciences/Stem cells/Haematopoietic stem cells Health sciences/Risk factors Myelofibrosis allogeneic stem cell transplant pulmonary infiltrates pulmonary hypertension engraftment syndrome extramedullary hematopoiesis Figures Figure 1 Figure 2 Introduction Allogeneic hematopoietic cell transplantation (alloHCT) is the only potentially curative modality for primary and secondary myelofibrosis due to other myeloproliferative neoplasms (MPN).[ 1 ] Although alloHCT is associated with favorable long-term outcomes, there is high non-relapse mortality (NRM) post-transplant which could be as high as 35%.[ 2 ] This relatively high NRM is likely contributed by advanced age, comorbid conditions, and organ dysfunction that frequently exists in these patients [ 3 ]. Engraftment syndrome (ES) is a clinical condition characterized by fever, skin rash, pulmonary infiltrates, weight gain, hepatic and/or renal dysfunction, and, in rare cases, encephalopathy. It typically arises around the time of neutrophil engraftment and can carry a significant risk of multi-organ failure and even death.[ 4 – 6 ] Although diagnostic criteria for ES have been proposed, it remains a diagnosis of exclusion, and its reported incidence varies widely due to the lack of universally accepted definitions. In the literature, the incidence of ES ranges from 7–90% depending on the study[ 7 ] ES has been associated with adverse outcomes following hematopoietic cell transplantation (HCT). In a cohort of 927 pediatric patients undergoing alloHCT, Chang et al. reported a significantly higher incidence of grade 2–4 acute graft-versus-host disease (75% vs. 34%), increased 2-year non-relapse mortality (38% vs. 19%), and lower overall survival at two years (38% vs. 54%) among those who developed ES compared to those who did not (P < 0.001) [ 8 ] The variability in ES incidence may be influenced by differences in patient populations, transplant characteristics, and underlying disease biology. While the exact pathophysiology remains unclear, inflammatory cytokine release is believed to play a central role, leading to capillary leak, systemic symptoms, and organ dysfunction.[ 4 , 7 ] In patients with myelofibrosis undergoing allogeneic hematopoietic cell transplantation (alloHCT), we have observed prominent pulmonary manifestations emerging during neutrophil engraftment, characterized by pulmonary infiltrates with or without associated hypoxemia. This clinical presentation may be related to pulmonary extramedullary hematopoiesis (EMH), a phenomenon well-documented in patients with myelofibrosis. [ 9 , 10 ]. Therefore, we aimed to further characterize this engraftment-related pulmonary complication in myelofibrosis and assess its association with pre-transplant patient and disease characteristics, as well as its impact on transplant outcomes. Previously, we reported on the prevalence of pulmonary arterial hypertension (PAH) in myelofibrosis and its association with adverse outcomes following alloHCT [ 11 ]. Accordingly, we also sought to investigate whether these pulmonary manifestations were associated with pre-transplant pulmonary assessments, with a particular focus on pulmonary arterial hypertension (PAH). Methods Patients This study was approved by the Institutional Review Board of City of Hope Medical Center. Using our institutional transplant database, we identified 83 patients with primary or secondary myelofibrosis who underwent allogeneic hematopoietic cell transplantation (alloHCT) between 2015 and 2020. Comprehensive data were collected from medical records, including patient demographics, disease characteristics, disease status at the time of transplant, molecular mutations, transplant-related variables, and clinical outcomes. Definition of engraftment syndrome Pulmonary manifestations of engraftment were defined as the new onset of pulmonary opacities—occurring within 96 hours before or after neutrophil engraftment—in the absence of infection, fluid overload, or left ventricular dysfunction, with or without accompanying hypoxemia. All included patients had documented neutrophil engraftment following stem cell infusion. Additional clinical features consistent with engraftment syndrome were recorded, including non-infectious fever, erythematous rash not attributed to graft-versus-host disease (GvHD), hepatic dysfunction, acute kidney injury, and encephalopathy. Statistical analysis Descriptive statistics were used to summarize baseline demographic, disease-related, and transplant characteristics. Associations between baseline variables and the occurrence of pulmonary manifestations were evaluated using Fisher’s exact test for univariate analysis and exact logistic regression models for multivariable analysis. Hematopoietic cell transplantation (HCT) outcomes stratified by the presence or absence of pulmonary complications during engraftment were assessed using Kaplan-Meier survival curves and log-rank tests for overall survival (OS), and cumulative incidence functions with Gray’s test for non-relapse mortality (NRM) and engraftment endpoints. All statistical tests were two-sided, with a significance threshold of P < 0.05. Results Patient demographics and baseline characteristics Of the 83 patients included in this study, 49% had primary myelofibrosis (PMF), while 51% had secondary MF arising from another myeloproliferative neoplasm (MPN). The median age was 62 years (range, 55–68), and the majority were male (n = 53, 64%). The JAK2 V617F mutation was identified in 65% of patients (n = 54). Prior to undergoing alloHCT, 61% (n = 51) had received ruxolitinib therapy. The median spleen size was 20 cm (range, 16–23 cm), and more than 90% of patients exhibited ≥ MF2 grade bone marrow fibrosis. Detailed patient characteristics are summarized in Table 1 . Table 1. Patient and HCT characteristics Total (N=83) Age at HCT, years Median 62 Interquartile range 55, 68 Range (17-75) Recipient sex Male 53 (63.9%) Female 30 (36.1%) Karnofsky performance status % Missing 3 (3.6%) 70 6 (7.2%) 80 31 (37.3%) 90 35 (42.2%) 100 8 (9.6%) 80-100 74 (89.2%) <80 6 (7.2%) Unknown 3 (3.6%) HCT Comorbidity Index Median 2 Interquartile range 0, 3 Range (0-7) 0 21 (25.3%) 1-2 24 (28.9%) ≥ 34 (41%) Unknown 4 (4.8%) Primary MF Yes 41 (49.4%) No 42 (50.6%) JAK2 mutation Yes 54 (65.1%) No 29 (34.9%) Degree of marrow fibrosis Missing 2 (2.4%) 1+ 6 (7.2%) 2+ 33 (39.8%) 3+ 42 (50.6%) Ruxolitinib therapy Yes 50 (60.2%) No 33 (39.8%) Pre HCT EF N 81 Median 61 Interquartile range 60, 65 Range (45-69) Pre HCT PASP (mmhg) N 79 Median 28 Interquartile range 20, 34 Range (3-74) Pre HCT Spleen Size (cm) N 75 Median 20 Interquartile range 16, 23 Range (10-34) Year of HCT 2015 17 (20.5%) 2016 12 (14.5%) 2017 14 (16.9%) 2018 15 (18.1%) 2019 21 (25.3%) 2020 4 (4.8%) Donor Type MRD 19 (22.9%) MUD 45 (54.2%) MMUD 10 (12%) Haplo 9 (10.8%) Donor sex Male 60 (72.3%) Female 23 (27.7%) Female donor to male recipient Yes 13 (15.7%) No 70 (84.3%) Donor age Median 36 Interquartile range 27, 47 Range (18-69) Graft Source Bone Marrow 2 (2.4%) Peripheral Blood Stem Cells 81 (97.6%) ABO blood group compatibility ABO compatible 48 (57.8%) Minor mismatch (donor is O) 13 (15.7%) Major mismatch (Recipient is O) 15 (18.1%) Bidirectional (None are O) 7 (8.4%) Donor/Recipient CMV serostatus D-/R- 14 (16.9%) D-/R+ 29 (34.9%) D+/R- 8 (9.6%) D+/R+ 32 (38.6%) Conditioning regimen BUSULFAN/CTX 4 (4.8%) FLUDARABINE/BUSULFAN 1 (1.2%) FLUDARABINE/CTX/TBI 1 (1.2%) FLUDARABINE/MELPHALAN 67 (80.7%) FLUDARABINE/MELPHALAN/Ruxolitinib/ 2 (2.4%) FLUDARABINE/MELPHALAN/TBI 7 (8.4%) FTBI/FLUDARABINE 1 (1.2%) Conditioning Regimen Intensity Myeloblative 5 (6%) Non-myeloablative/Reduced Intensity 78 (94%) GVHD prophylaxis CTX/TACROLIMUS/CELLCEPT 14 (16.9%) TACROLIMUS/MTX 5 (6%) TACROLIMUS/MTX/BORTEZOMIB 1 (1.2%) TACROLIMUS/SIROLIMUS 48 (57.8%) TACROLIMUS/SIROLIMUS/MTX 3 (3.6%) TACROLIMUS/SIROLIMUS/OTHER 1 (1.2%) TACROLIMUS/SIROLIMUS/Ruxolitinib 11 (13.3%) HCT= Hematopoietic Cell Transplantation, GVHD= graft versus host disease CMV=cytomegalovirus EF=Ejection fraction, PASP=pulmonary artery systolic pressure Hematopoietic Cell Transplantation . The median Hematopoietic Cell Transplantation–Comorbidity Index (HCT-CI) score was 2 (range, 0–7). The most common graft source for alloHCT was a matched unrelated donor (MUD) in 54% of cases, followed by matched related donors (MRD) in 23%, mismatched unrelated donors (MMUD) in 12%, and haploidentical donors in 11%. Mobilized peripheral blood stem cells were utilized in 97.6% of transplants. The majority of patients (83%) received a fludarabine-melphalan conditioning regimen. For graft-versus-host disease (GVHD) prophylaxis, tacrolimus combined with sirolimus was used in 57.8% of patients (n = 48). The median CD34 + cell dose infused was 6.0 × 10⁶ cells/kg (range, 2.49–12.96), and the median CD3 + cell dose was 2.21 × 10⁶ cells/kg (range, 0.25–4.90). Neutrophil engraftment occurred at a median of 20 days, and platelet engraftment at a median of 37 days. Additional transplant-related details are summarized in Table 1 . Pulmonary manifestations of engraftment Pulmonary infiltrates were observed in 25 patients (30%) at the time of neutrophil engraftment. Radiologic findings included ground-glass opacities, areas of consolidation, and pulmonary nodules. In 18 of these patients (72%), the pulmonary findings were attributed to engraftment-related complications. Eight patients (44%) required admission to the intensive care unit (ICU). Hypoxemia was present in 15 patients (83%), of whom six (40%) required mechanical ventilation. Among the remaining hypoxemic patients, two (13%) required high-flow oxygen, while seven (47%) were managed with low-flow oxygen via nasal cannula (2–6 L/min). Additional symptoms consistent with engraftment syndrome included fever (33%), diarrhea (33%), and rash (22%). Half of the patients with pulmonary manifestations (n = 9) were treated with systemic corticosteroids. Risk factors for pulmonary complications during engraftment The association between pre-transplant pulmonary parameters and the development of pulmonary complications during engraftment is summarized in Table 2 . Demographic factors and transplant-related characteristics did not reveal any significant predictors of pulmonary involvement, as detailed in Table 3 . Pre-transplant chest CT scans were reported as normal in 87% of patients. Among the 18 patients who developed pulmonary manifestations of engraftment, 9 had small pulmonary nodules (≤ 5 mm) identified on pre-HCT imaging. Representative CT images from two of these patients are shown in Fig. 1 . Table 2 Association of disease and HCT factors with occurrence of Pulmonary Complications of Engraftment Syndrome (PES) PES N Yes No Fisher's exact test p value Adjusted OR (95%CI)* P value* Age at HCT (years) < 65 44 9(20.5%) 35(79.5%) 0.80 Reference 1.00 ≥ 65 39 9(23.1%) 30(76.9%) 0.88(0.24,3.05) Sex M 53 11(20.8%) 42(79.2%) 0.79 Reference 1.00 F 30 7(23.3%) 23(76.7%) 1.07(0.29,3.74) KPS, % 90–100 43 10(23.3%) 33(76.7%) 0.79 Reference 1.00 ≤ 80 37 7(18.9%) 30(81.1%) 0.86(0.23,3.04) HCT Comorbidity Index 0 21 4(19.0%) 17(81.0%) 0.62 Reference 0.74 1–2 25 7(28.0%) 18(72.0%) 1.67(0.28,11.02) ≥ 3 34 6(17.6%) 28(82.4%) 0.98(0.19,5.71) Donor Matched 64 13(20.3%) 51(79.7%) 0.54 Reference 0.74 MMUD or Haplo 19 5(26.3%) 14(73.7%) 1.28(0.28,5.23) Female to Male HCT No 70 16(22.9%) 54(77.1%) 0.72 Reference 0.71 Yes 13 2(15.4%) 11(84.6%) 0.53(0.05,3.00) Primary MF Yes 41 8(19.5%) 33(80.5%) 0.79 Reference 0.79 No 42 10(23.8%) 32(76.2%) 1.18(0.34,4.17) JAK2 mutation Yes 54 14(25.9%) 40(74.1%) 0.27 Reference 0.16 No 29 4(13.8%) 25(86.2%) 0.39(0.08,1.50) Degree of fibrosis (MF grade) 1 + or 2+ 39 9(23.1%) 30(76.9%) 1.00 Reference 1.00 3+ 42 9(21.4%) 33(78.6%) 0.88(0.24,3.24) Ruxolitinib use Yes 50 14(28.0%) 36(72.0%) 0.11 Reference 0.099 No 33 4(12.1%) 29(87.9%) 0.35(0.07,1.34) Pre HCT EF ≤ 60 40 11(27.5%) 29(72.5%) 0.30 Reference 0.77 > 60 41 7(17.1%) 34(82.9%) 0.74(0.20,2.70) Pre BMT PASP (mmHg) ≤ 28 43 4(9.3%) 39(90.7%) 0.011 Reference 0.011 > 28 36 12(33.3%) 24(66.7%) 4.78(1.26,22.69) < 35 61 9(14.8%) 52(85.2%) 0.042 Reference 0.042 ≥ 35 18 7(38.9%) 11(61.1%) 3.68(1.13,12.00) Pre HCT Spleen Size (cm) < 20 39 6(15.4%) 33(84.6%) 0.26 Reference 0.23 ≥ 20 36 10(27.8%) 26(72.2%) 2.21(0.54,9.82) Pre HCT CT chest finding Normal 72 17(23.6%) 55(76.4%) 0.44 Reference 0.42 Abnormal 11 1(9.1%) 10(90.9%) 0.29(0.01,2.52) Pre HCT FEV1 ≥ 80% 63 11(17.5%) 52(82.5%) 0.28 Reference 0.25 < 80% 15 5(33.3%) 10(66.7%) 2.60(0.50,13.32) Pre HCT FEV1/FVC ≥ 70% 60 13(21.7%) 47(78.3%) 0.75 Reference 1.00 < 70% 18 3(16.7%) 15(83.3%) 0.84(0.08,5.40) Pre HCT DLCO ≥ 80% 21 5(23.8%) 16(76.2%) 0.76 Reference 0.74 < 80% 56 11(19.6%) 45(80.4%) 0.79(0.18,4.10) * Based on exact logistic regression adjusting for Pre HCT pulmonary pressure Table 3 Association of patient and HCT characteristics with OS and NRM Overall Survival NRM N 1 Yr (95%CI)* HR (95%CI)* P* Adjusted HR (95%CI)† P† 100 day (95%CI)* HR (95%CI)* P* Adjusted HR (95%CI) † P† Age at HCT, years < 65 44 0.656(0.494,0.776) Reference 0.82 Reference 0.56 0.114(0.041,0.227) Reference 0.71 Reference 0.67 ≥ 65 39 0.615(0.445,0.747) 1.08(0.55,2.11) 1.22(0.62,2.40) 0.205(0.095,0.344) 1.13(0.51,2.51) 1.19(0.53,2.66) Sex M 53 0.657(0.512,0.769) Reference 0.65 Reference 0.64 0.132(0.057,0.238) Reference 0.81 Reference 0.84 F 30 0.600(0.405,0.750) 1.16(0.59,2.29) 1.18(0.58,2.41) 0.200(0.079,0.360) 1.16(0.51,2.61) 1.09(0.47,2.51) KPS, % 90–100 43 0.647(0.484,0.771) Reference 0.90 Reference 0.83 0.186(0.086,0.315) Reference 0.31 Reference 0.25 ≤ 80 37 0.649(0.473,0.779) 0.96(0.48,1.90) 0.93(0.47,1.85) 0.108(0.034,0.233) 0.63(0.27,1.48) 0.60(0.25,1.44) HCT Comorbidity Index 0 21 0.571(0.338,0.749) Reference 0.15 Reference 0.81 0.238(0.083,0.437) Reference 0.53 Reference 0.67 1–2 25 0.513(0.304,0.689) 0.89(0.40,2.01) 1.13(0.46,2.79) 0.120(0.029,0.280) 0.67(0.25,1.79) 0.72(0.26,1.99) ≥ 3 34 0.765(0.584,0.875) 0.48(0.21,1.13) 0.84(0.33,2.11) 0.147(0.053,0.287) 0.60(0.23,1.56) 0.65(0.25,1.71) Donor Matched 64 0.686(0.556,0.784) Reference 0.065 Reference 0.022 0.125(0.058,0.219) Reference 0.25 Reference 0.27 MMUD or Haplo 19 0.474(0.244,0.673) 1.92(0.94,3.93) 2.41(1.13,5.11) 0.263(0.092,0.474) 1.66(0.68,4.05) 1.66(0.68,4.05) Female to Male HCT No 70 0.627(0.503,0.729) Reference 0.94 Reference 0.81 0.157(0.083,0.252) Reference 0.77 Reference 0.82 Yes 13 0.692(0.373,0.872) 0.96(0.37,2.48) 1.12(0.43,2.92) 0.154(0.022,0.399) 1.15(0.41,3.27) 1.13(0.40,3.20) Primary MF Yes 41 0.707(0.543,0.822) Reference 0.34 Reference 0.75 0.171(0.074,0.301) Reference 0.51 Reference 0.44 No 42 0.568(0.405,0.702) 1.37(0.70,2.67) 1.12(0.56,2.23) 0.143(0.057,0.266) 1.34(0.60,2.99) 1.38(0.61,3.10) JAK2 mutation Yes 54 0.630(0.487,0.743) Reference 0.99 Reference 0.66 0.167(0.081,0.278) Reference 0.52 Reference 0.57 No 29 0.651(0.448,0.795) 1.00(0.50,1.98) 1.18(0.56,2.50) 0.138(0.042,0.289) 0.78(0.34,1.78) 0.79(0.34,1.81) Degree of marrow fibrosis 1 + or 2+ 39 0.615(0.445,0.747) Reference 0.34 Reference 0.30 0.205(0.095,0.344) Reference 0.35 Reference 0.45 3+ 42 0.687(0.522,0.805) 0.72(0.36,1.43) 0.68(0.33,1.41) 0.119(0.043,0.237) 0.65(0.28,1.52) 0.71(0.29,1.72) Ruxolitinib therapy Yes 50 0.640(0.491,0.756) Reference 0.78 Reference 0.46 0.160(0.074,0.275) Reference 0.68 Reference 0.64 No 33 0.632(0.442,0.772) 1.10(0.56,2.14) 1.32(0.63,2.77) 0.152(0.054,0.295) 1.21(0.55,2.66) 1.21(0.55,2.67) Pre HCT EF ≤ 60 40 0.721(0.553,0.835) Reference 0.87 Reference 0.65 0.125(0.045,0.248) Reference 0.50 Reference 0.55 > 60 41 0.585(0.420,0.718) 1.06(0.53,2.09) 0.84(0.41,1.74) 0.195(0.090,0.329) 1.32(0.57,3.05) 1.30(0.56,2.99) Pre HCT PASP(mmHg) ≤ 28 43 0.674(0.513,0.793) Reference 0.46 Reference 0.10 0.140(0.056,0.261) Reference 0.81 Reference 0.83 > 28 36 0.636(0.457,0.770) 1.28(0.64,2.57) 1.88(0.88,4.00) 0.194(0.084,0.338) 1.14(0.50,2.61) 1.09(0.48,2.47) < 35 61 0.719(0.587,0.815) Reference 0.007 Reference < 0.001 0.115(0.050,0.209) Reference 0.031 Reference 0.040 ≥ 35 18 0.444(0.216,0.651) 2.58(1.24,5.40) 4.68(1.93,11.37) 0.333(0.131,0.552) 2.55(1.07,6.08) 2.42(1.04,5.62) Pre HCT Spleen Size (cm) < 20 39 0.872(0.719,0.945) Reference < 0.001 Reference < 0.001 0.103(0.032,0.222) Reference 0.083 Reference 0.094 ≥ 20 36 0.444(0.280,0.596) 3.70(1.67,8.22) 4.14(1.83,9.36) 0.194(0.084,0.338) 2.18(0.88,5.39) 2.17(0.88,5.38) Pre HCT CT chest finding Normal 72 0.651(0.528,0.749) Reference 0.42 Reference 0.19 0.139(0.071,0.229) Reference 0.47 Reference 0.60 Abnormal 11 0.545(0.229,0.780) 1.42(0.59,3.44) 1.84(0.75,4.55) 0.273(0.058,0.552) 1.47(0.50,4.33) 1.36(0.44,4.22) Pre HCT FEV1 ≥ 80% 63 0.635(0.504,0.740) Reference 0.66 Reference 0.96 0.175(0.093,0.278) Reference 0.17 Reference 0.21 < 80% 15 0.660(0.365,0.843) 0.82(0.34,1.99) 1.03(0.41,2.54) 0.067(0.004,0.270) 0.38(0.09,1.60) 0.39(0.09,1.68) Pre HCT FEV1/FVC ≥ 70% 60 0.631(0.496,0.740) Reference 0.45 Reference 0.80 0.150(0.073,0.252) Reference 0.67 Reference 0.97 < 70% 18 0.667(0.404,0.834) 0.72(0.30,1.73) 0.88(0.35,2.27) 0.167(0.039,0.372) 0.78(0.26,2.29) 0.98(0.32,3.03) Pre HCT DLCO ≥ 80% 21 0.714(0.472,0.860) Reference 0.24 Reference 0.064 0.048(0.003,0.202) Reference 0.37 Reference 0.39 < 80% 56 0.624(0.484,0.736) 1.68(0.69,4.08) 2.36(0.95,5.87) 0.196(0.104,0.310) 1.66(0.58,4.73) 1.59(0.55,4.58) PES No 65 0.677(0.549,0.776) Reference 0.062 Reference 0.074 0.138(0.068,0.234) Reference 0.26 Reference 0.26 Yes 18 0.500(0.259,0.701) 1.94(0.95,3.96) 1.93(0.94,3.97) 0.222(0.065,0.436) 1.65(0.70,3.89) 1.63(0.70,3.83) * based on univariate analysis, log-rank test for OS, and Gray’s test for NRM PES: Pulmonary complications of engraftment syndrome † Based on multivariable Cox regression model for OS adjusting for donor type and pre BMT spleen size, and Fine and Gray regression model for NRM adjusting for donor type. Pulmonary hypertension is a well-recognized comorbidity in patients with myelofibrosis. Pulmonary artery systolic pressure (PASP) measurements were available for 79 patients in this cohort, with a median PASP of 28 mmHg (range, 3–74 mmHg). Pulmonary arterial hypertension (PAH), defined as PASP ≥ 35 mmHg, was identified in 61 patients (77%). The presence of PAH was significantly associated with an increased risk of developing pulmonary complications during engraftment, with an odds ratio of 3.68 (95% CI: 1.13–12; P = 0.04). Abnormal pulmonary function tests (PFTs) prior to transplant were identified in a substantial proportion of patients: reduced FEV1 (< 80%) in 19%, FEV1/FVC ratio < 70% in 23%, and decreased DLCO (< 80%) in 72%. However, no significant association was observed between these pre-HCT PFT abnormalities and the development of pulmonary complications during engraftment. Specifically, the association between pulmonary complications and FEV1 (95% CI: 0.50–13.32; P = 0.25), FEV1/FVC (95% CI: 0.08–5.40; P = 1.00), and DLCO (95% CI: 0.18–4.10; P = 0.74). Spleen size was not significantly associated with the development of pulmonary complications during engraftment (P = 0.23; 95% CI: 0.54–9.82). Although neutrophil engraftment occurred earlier in patients who developed pulmonary complications (median 17 days vs. 20 days), this difference did not reach statistical significance (P = 0.20). Overall Survival (OS) and Non-Relapse Mortality (NRM) The 12-month and 2-year overall survival (OS) rates were 65% and 63%, respectively. Day 100 mortality was 16%, and the 2-year non-relapse mortality (NRM) rate was 24% ( Fig. 2 ). There was no statistically significant difference in OS or NRM between patients who developed pulmonary complications during engraftment and those who did not (HR;1.93, 95% CI 0.94–3.97, P 0.074 and HR 1.63; 95% CI 0.70–3.83, P 0.26, respectively). The median ICU stay for patients who developed pulmonary manifestations was 18 days. In multivariate analysis, patients with a pre-HCT pulmonary artery systolic pressure (PASP) > 35 mmHg and a spleen size > 20 cm had significantly worse overall survival (OS (HR 2.58, 95% CI 1.24–5.40, P < 0.001, and HR 4.14, 95% CI 1.83–9.36, p < 0.001), respectively. Additionally, a PASP ≥ 35 mmHg was associated with increased non-relapse mortality (NRM) (HR 2.42, 95% CI: 1.04–5.62; P = 0.040). Patient, donor, and transplant characteristics and their association with OS and NRM are listed in Table 3 . Discussion In this study, we describe a distinct presentation of engraftment syndrome (ES) characterized predominantly by pulmonary infiltrates and respiratory symptoms occurring around the time of neutrophil engraftment in patients undergoing alloHCT for myelofibrosis. Notably, only one-third of these patients exhibited extrapulmonary features typically associated with ES. While this complication did not correlate with decreased overall survival (OS) or increased non-relapse mortality (NRM), it was associated with substantial morbidity. These findings highlight the importance of early recognition and prompt initiation of corticosteroid therapy, which appeared to be effective in managing this syndrome. Although the precise mechanism underlying pulmonary complications during engraftment in myelofibrosis remains unclear, the findings suggest a potential link to pulmonary extramedullary hematopoiesis (EMH) and pulmonary arterial hypertension (PAH)—both of which are distinctive comorbidities in MF patients undergoing alloHCT. Cardiopulmonary morbidity is frequently observed in this population, with PAH being a particularly common and clinically significant condition. In prior work, we demonstrated that PAH is prevalent among patients with MF and is associated with increased morbidity and mortality following alloHCT. [ 11 ]. In that study, PAH was identified in up to 50% of patients prior to transplantation and was associated with significantly worse outcomes, including reduced overall survival (58.9% vs. 88.8%, P = 0.025) and increased non-relapse mortality (21.6% vs. 7.1%, P = 0.007).[ 11 ] In the current cohort, we further validate the association between pre-transplant PAH and adverse transplant outcomes. Moreover, we demonstrate a link between PAH and the development of pulmonary complications during engraftment. Additional contributors to cardiopulmonary morbidity in MF may include hemodynamic alterations related to splenomegaly and portal hypertension, as well as underlying chronic thromboembolic processes. Pulmonary extramedullary hematopoiesis (EMH) has been documented in multiple reports involving patients with myelofibrosis, whether primary or secondary to another myeloproliferative neoplasm (MPN). Evidence of pulmonary EMH has been demonstrated both histologically through biopsy specimens and non-invasively using technetium sulfur colloid scintigraphy. [ 9 , 10 , 12 ]. Pulmonary EMH has also been implicated in the pathogenesis of PAH in myelofibrosis. Involvement of the pulmonary arteries by EMH, along with associated arteriopathy, has been demonstrated in biopsy specimens, suggesting a potential mechanistic link between EMH and pulmonary vascular remodeling in this setting. [ 9 , 12 , 13 ]. The observed association between pulmonary manifestations of engraftment and PAH in this study may, in part, be explained by the contribution of pulmonary extramedullary hematopoiesis (EMH) to the development of PAH in myelofibrosis. It is plausible that donor cell engraftment within foci of pulmonary EMH could underlie the pathogenesis of these complications. Routine chest CT imaging appears to be relatively insensitive for detecting pulmonary EMH, especially in the absence of symptoms. In our cohort of 18 patients who developed pulmonary complications during engraftment, only half had small nodules (< 1 cm) identified on pre-transplant CT imaging. Given the potential prognostic implications of pulmonary EMH for transplant outcomes, specialized imaging modalities—such as magnetic resonance imaging (MRI), Indium-111-labeled leukocyte scans, or technetium sulfur colloid scintigraphy—may be valuable for assessing the extent of pulmonary EMH. This may be particularly useful in MF patients with abnormal pre-transplant chest imaging or known PAH to aid in pre-HCT risk stratification. A range of radiologic findings has been reported in patients with pulmonary EMH, including ground-glass opacities, areas of consolidation, pulmonary nodules, and pleural effusions [ 9 , 13 – 15 ]. Similar imaging features were observed in our cohort of patients who developed pulmonary complications during engraftment. Representative pre- and post-transplant chest CT images from selected patients in our study who developed pulmonary engraftment syndrome (PES) are shown in Fig. 2 . The use of ruxolitinib in the pre-transplant and immediate post-transplant period may have a favorable impact on mitigating pulmonary manifestations of engraftment. Its immunomodulatory and anti-inflammatory properties could potentially reduce pulmonary inflammation and extramedullary hematopoiesis. Importantly, the use of ruxolitinib during the peritransplant period has been shown to be safe and is not associated with adverse effects on hematopoietic engraftment [ 16 ]. Case reports have also documented improvement in pulmonary EMH and associated respiratory parameters following treatment with ruxolitinib, suggesting that it may serve as a beneficial intervention prior to alloHCT to optimize pulmonary function and reduce respiratory complications. [ 17 – 19 ]. Both pulmonary arterial hypertension (PAH) and pulmonary extramedullary hematopoiesis (EMH) associated with myelofibrosis have been shown to improve following successful alloHCT [ 11 , 14 ] In our study, the occurrence of pulmonary complications during engraftment was not associated with increased non-relapse mortality (NRM), and all affected patients were successfully managed with supportive care and/or corticosteroids. Although a definitive diagnosis requires exclusion of infectious etiologies, increased awareness of this clinical entity may facilitate earlier initiation of corticosteroid therapy, potentially preventing respiratory deterioration and associated morbidity during the immediate post-transplant period. Early recognition may also help avoid unnecessary invasive procedures, such as lung biopsy, and a trial of empiric corticosteroids should be considered once infections have been ruled out through bronchoalveolar lavage. Given the observed association between PAH and pulmonary complications during engraftment, patients with pre-existing PAH should be closely monitored during the engraftment phase for early signs of this syndrome. Declarations Authorship Statement V.P. developed the study concept. S.O. and I.A. conducted the study and were responsible for data collection. D.S. assisted with data acquisition. D.Y. performed the statistical analysis. S.R. reviewed and interpreted the imaging studies. V.P., S.O., and I.A. drafted the initial version of the manuscript. All authors contributed intellectual input and participated in the critical revision and final approval of the manuscript. Conflicts of interest HA and MAM have received research support from Incyte. The remaining authors have no relevant conflicts of interest to declare. References Ali H, Pullarkat V, Snyder D. Biology and Current Treatment of Myeloproliferative Neoplasms. Cancer Treat Res. 2021;181:151-165. doi:10.1007/978-3-030-78311-2_9 Choudhary D, Doval D, Khandelwal V, Setia R, Handoo A. Allogeneic stem cell transplant for myelofibrosis- A retrospective single-center study. Blood Cell Ther. 2023;6:5-10. Published 2023 Feb 10. doi:10.31547/bct-2022-003 Acosta-Medina AA, Baranwal A, Johnson IM, et al. Comparison of Pretransplantation Prediction Models for Nonrelapse Mortality in Patients with Myelofibrosis Undergoing Allogeneic Stem Cell Transplantation. Transplant Cell Ther. 2023;29 :360.e1-360.e8. doi:10.1016/j.jtct.2023.02.002 Spitzer TR. Engraftment syndrome following hematopoietic stem cell transplantation. Bone Marrow Transplant. 2001;27:893-898. doi:10.1038/sj.bmt.1703015 Nürnberger W, Willers R, Burdach S, Göbel U. Risk factors for capillary leakage syndrome after bone marrow transplantation. Ann Hematol. 1997;74:221-224. doi:10.1007/s002770050288 Cahill RA, Spitzer TR, Mazumder A. Marrow engraftment and clinical manifestations of capillary leak syndrome. Bone Marrow Transplant. 1996;18:177-184. Spitzer TR. Engraftment syndrome: double-edged sword of hematopoietic cell transplants. Bone Marrow Transplant. 2015;50:469-475. doi:10.1038/bmt.2014.296 Chang L, Frame D, Braun T, et al. Engraftment syndrome after allogeneic hematopoietic cell transplantation predicts poor outcomes. Biol Blood Marrow Transplant. 2014;20:1407-1417. doi:10.1016/j.bbmt.2014.05.022 Singh I, Mikita G, Green D, Risquez C, Sanders A. Pulmonary extra-medullary hematopoiesis and pulmonary hypertension from underlying polycythemia vera: a case series. Pulm Circ. 2017;7:261-267. Published 2017 Mar 10. doi:10.1177/2045893217702064 Yang M, Covington MF, Nguyen BD, Johnson GB, Mesa RA, Roarke MC. 99m Tc-Sulfur Colloid Bone Marrow Scintigraphy in Diagnosis of Diffuse Pulmonary Extramedullary Hematopoiesis Secondary to Myelofibrosis. J Nucl Med Technol. 2018;46:368-372. doi:10.2967/jnmt.118.210534 Gupta R, Jamal F, Yang D, et al. Pulmonary hypertension is associated with increased nonrelapse mortality after allogeneic hematopoietic cell transplantation for myelofibrosis. Bone Marrow Transplant. 2020;55:877-883. doi:10.1038/s41409-019-0741-8 Singh H, Kurman JS, Jani CT, Rao N, Benn BS. An 80-year-old woman with myelofibrosis and diffuse mosaic attenuation on chest computed tomography. Respir Med Case Rep. 2022;38:101705. Published 2022 Jul 11. doi:10.1016/j.rmcr.2022.101705 Wyatt SH, Fishman EK. Diffuse pulmonary extramedullary hematopoiesis in a patient with myelofibrosis: CT findings. J Comput Assist Tomogr. 1994;18:815-817. doi:10.1097/00004728-199409000-00023 Chunduri S, Gaitonde S, Ciurea SO, Hoffman R, Rondelli D. Pulmonary extramedullary hematopoiesis in patients with myelofibrosis undergoing allogeneic stem cell transplantation. Haematologica. 2008;93:1593-1595. doi:10.3324/haematol.13203 Enokida K, Tomomatsu K, Okada N, et al. Transudative Pleural Effusion Associated with Extramedullary Hematopoiesis. Intern Med. 2021;60:449-452. doi:10.2169/internalmedicine.4668-20 Ali H, Tsai NC, Synold T, et al. Peritransplantation ruxolitinib administration is safe and effective in patients with myelofibrosis: a pilot open-label study. Blood Adv. 2022;6:1444-1453. doi:10.1182/bloodadvances.2021005035 Maccaferri M, Leonardi G, Marasca R, et al. Ruxolitinib for pulmonary extramedullary hematopoiesis in myelofibrosis. Leuk Lymphoma. 2014;55:2207-2208. doi:10.3109/10428194.2013.873538 Fujimoto A, Hamaguchi S, Suzuki R. Case of Pulmonary Extramedullary Hematopoiesis Responding to Ruxolitinib. Leuk Res Rep. 2022;17:100290. Published 2022 Feb 7. doi:10.1016/j.lrr.2022.100290 Tabarroki A, Lindner DJ, Visconte V, et al. Ruxolitinib leads to improvement of pulmonary hypertension in patients with myelofibrosis. Leukemia. 2014;28:1486-1493. doi:10.1038/leu.2014.5 Additional Declarations The authors have declared there is NO conflict of interest to disclose. Cite Share Download PDF Status: Published Journal Publication published 24 Sep, 2025 Read the published version in Bone Marrow Transplantation → Version 1 posted Editorial decision: revise 20 Jun, 2025 Review # 2 received at journal 13 Jun, 2025 Reviewer # 2 agreed at journal 12 Jun, 2025 Review # 1 received at journal 22 May, 2025 Reviewer # 1 agreed at journal 09 May, 2025 Reviewers invited by journal 06 May, 2025 Submission checks completed at journal 02 May, 2025 First submitted to journal 01 May, 2025 Unknown event 01 May, 2025 Editor assigned by journal 30 Apr, 2025 You are reading this latest preprint version Research Square lets you share your work early, gain feedback from the community, and start making changes to your manuscript prior to peer review in a journal. As a division of Research Square Company, we’re committed to making research communication faster, fairer, and more useful. We do this by developing innovative software and high quality services for the global research community. Our growing team is made up of researchers and industry professionals working together to solve the most critical problems facing scientific publishing. Also discoverable on Platform About Our Team In Review Editorial Policies Advisory Board Help Center Resources Author Services Accessibility API Access RSS feed Manage Cookie Preferences © Research Square 2026 | ISSN 2693-5015 (online) Privacy Policy Terms of Service Do Not Sell My Personal Information {"props":{"pageProps":{"initialData":{"identity":"rs-6568124","acceptedTermsAndConditions":true,"allowDirectSubmit":false,"archivedVersions":[],"articleType":"Article","associatedPublications":[],"authors":[{"id":452458398,"identity":"f3ea90d5-a023-4b54-a361-19689e72cbd6","order_by":0,"name":"Vinod Pullarkat","email":"data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAZAAAAAyAQMAAABI0h/eAAAABlBMVEX///8AAABVwtN+AAAACXBIWXMAAA7EAAAOxAGVKw4bAAAA00lEQVRIie3OrwrCUBTH8SODmzZWz0D0FTYuzLKHOSsmg2A1LC2J1q04X0EEMV4Y3OQDmHQW81aM4h02w/40kfstJ334HQCd7gdzb2IgCnUBDAGDqAu5EAiqCWPUm5huN+IkM1fQ8srtbFWV1QlGk82uhWRnReTCR2kdnPQMfHgp2lZMRRgFIK2jYcUQJiiaiY01eVEwluajBwlj8l1psg+xo2bCkM1FuCbuySl30hg5YrNQxNgX5ZO8bZ7fyyoORmi3PPadmkDqR1R9V3Q6ne7vewO6SEW7XrIYAQAAAABJRU5ErkJggg==","orcid":"https://orcid.org/0000-0001-9129-3424","institution":"City of Hope National Medical Center","correspondingAuthor":true,"prefix":"","firstName":"Vinod","middleName":"","lastName":"Pullarkat","suffix":""},{"id":452458399,"identity":"23db8e51-85fb-4614-a581-c68fc7d1121b","order_by":1,"name":"Salman Otoukesh","email":"","orcid":"","institution":"City of Hope National Medical Center","correspondingAuthor":false,"prefix":"","firstName":"Salman","middleName":"","lastName":"Otoukesh","suffix":""},{"id":452458400,"identity":"f80e5d05-94c3-408a-96ba-9c71d8180838","order_by":2,"name":"Idoroenyi Amanam","email":"","orcid":"","institution":"City of Hope National Medical Center","correspondingAuthor":false,"prefix":"","firstName":"Idoroenyi","middleName":"","lastName":"Amanam","suffix":""},{"id":452458401,"identity":"2298d0f8-fe94-407c-b358-3071affa5f7a","order_by":3,"name":"Dongyun Yang","email":"","orcid":"","institution":"City of Hope National Medical Center","correspondingAuthor":false,"prefix":"","firstName":"Dongyun","middleName":"","lastName":"Yang","suffix":""},{"id":452458402,"identity":"b50556b9-3690-4713-a9bd-b757cb754bcd","order_by":4,"name":"Diana Samuels","email":"","orcid":"","institution":"City of Hope","correspondingAuthor":false,"prefix":"","firstName":"Diana","middleName":"","lastName":"Samuels","suffix":""},{"id":452458403,"identity":"74cf4112-5859-4476-a784-91c03e4d1fb1","order_by":5,"name":"Amandeep Salhotra","email":"","orcid":"https://orcid.org/0000-0002-9302-5041","institution":"City of Hope National Medical Center","correspondingAuthor":false,"prefix":"","firstName":"Amandeep","middleName":"","lastName":"Salhotra","suffix":""},{"id":452458404,"identity":"c7fc0dfb-f45d-4931-a6d6-95968a2df607","order_by":6,"name":"Andrew Artz","email":"","orcid":"https://orcid.org/0000-0003-0803-9607","institution":"City of Hope","correspondingAuthor":false,"prefix":"","firstName":"Andrew","middleName":"","lastName":"Artz","suffix":""},{"id":452458405,"identity":"68147430-e8ab-456f-b274-4551387ba1bd","order_by":7,"name":"Shukaib Arslan","email":"","orcid":"https://orcid.org/0000-0002-8447-9607","institution":"City of Hope National Medical Center","correspondingAuthor":false,"prefix":"","firstName":"Shukaib","middleName":"","lastName":"Arslan","suffix":""},{"id":452458406,"identity":"23a4c762-c6dc-46a2-a99f-6759b60ba78f","order_by":8,"name":"Ibrahim Aldoss","email":"","orcid":"https://orcid.org/0000-0001-9564-4498","institution":"City of Hope National Medical Center","correspondingAuthor":false,"prefix":"","firstName":"Ibrahim","middleName":"","lastName":"Aldoss","suffix":""},{"id":452458407,"identity":"927de301-d127-4726-b25c-f0e5bfcef60b","order_by":9,"name":"Karamjeet Sandhu","email":"","orcid":"https://orcid.org/0000-0001-8024-8484","institution":"City of Hope National Medical Center","correspondingAuthor":false,"prefix":"","firstName":"Karamjeet","middleName":"","lastName":"Sandhu","suffix":""},{"id":452458408,"identity":"5cfe61d1-d1ba-4bb9-8178-af8f12c3aae3","order_by":10,"name":"Paul Koller","email":"","orcid":"https://orcid.org/0000-0003-3830-5320","institution":"City of Hope","correspondingAuthor":false,"prefix":"","firstName":"Paul","middleName":"","lastName":"Koller","suffix":""},{"id":452458409,"identity":"2a8ae3e7-086b-4616-9d6a-4e2d784e8e02","order_by":11,"name":"Ahmed Aribi","email":"","orcid":"","institution":"City of Hope National Medical Center","correspondingAuthor":false,"prefix":"","firstName":"Ahmed","middleName":"","lastName":"Aribi","suffix":""},{"id":452458410,"identity":"3ac46f6e-aaca-4733-bd4f-af4ffd096743","order_by":12,"name":"Peter Curtin","email":"","orcid":"","institution":"City of Hope","correspondingAuthor":false,"prefix":"","firstName":"Peter","middleName":"","lastName":"Curtin","suffix":""},{"id":452458411,"identity":"cf76945a-6e9c-4d52-af37-229b30634de7","order_by":13,"name":"Anthony Stein","email":"","orcid":"","institution":"City of Hope National Medical Center","correspondingAuthor":false,"prefix":"","firstName":"Anthony","middleName":"","lastName":"Stein","suffix":""},{"id":452458412,"identity":"83d89ec8-c102-495c-9961-9f9460909201","order_by":14,"name":"Guido Marcucci","email":"","orcid":"","institution":"City of Hope","correspondingAuthor":false,"prefix":"","firstName":"Guido","middleName":"","lastName":"Marcucci","suffix":""},{"id":452458413,"identity":"689683d1-5ac4-45a3-b620-9091be8c90e5","order_by":15,"name":"Monzr Al Malki","email":"","orcid":"https://orcid.org/0000-0001-8226-471X","institution":"City of Hope","correspondingAuthor":false,"prefix":"","firstName":"Monzr","middleName":"Al","lastName":"Malki","suffix":""},{"id":452458414,"identity":"e0cb0c74-8585-4e50-bbb5-6eb412a7ad36","order_by":16,"name":"Haris Ali","email":"","orcid":"https://orcid.org/0000-0002-9728-7292","institution":"City of Hope National Medical Center","correspondingAuthor":false,"prefix":"","firstName":"Haris","middleName":"","lastName":"Ali","suffix":""},{"id":452458415,"identity":"8b778098-5004-47c0-b872-72da3e6f7308","order_by":17,"name":"Ryotaro Nakamura","email":"","orcid":"https://orcid.org/0000-0002-9082-0680","institution":"City of Hope","correspondingAuthor":false,"prefix":"","firstName":"Ryotaro","middleName":"","lastName":"Nakamura","suffix":""},{"id":452458416,"identity":"08d31bd3-999d-4c69-9535-5cdb7717dffe","order_by":18,"name":"Vinod Pullarkat","email":"","orcid":"","institution":"City of Hope National Medical Center","correspondingAuthor":false,"prefix":"","firstName":"Vinod","middleName":"","lastName":"Pullarkat","suffix":""}],"badges":[],"createdAt":"2025-04-30 22:50:09","currentVersionCode":1,"declarations":"","doi":"10.21203/rs.3.rs-6568124/v1","doiUrl":"https://doi.org/10.21203/rs.3.rs-6568124/v1","draftVersion":[],"editorialEvents":[{"content":"https://doi.org/10.1038/s41409-025-02724-w","type":"published","date":"2025-09-24T04:00:00+00:00"}],"editorialNote":"","failedWorkflow":false,"files":[{"id":82375146,"identity":"4352f7c3-b38e-4b4e-af57-e347c153b61d","added_by":"auto","created_at":"2025-05-09 14:27:22","extension":"jpg","order_by":1,"title":"Figure 1","display":"","copyAsset":false,"role":"figure","size":797711,"visible":true,"origin":"","legend":"\u003cp\u003eRepresentative CT images from 2 patients prior to HCT and during development of pulmonary manifestations of ES are shown. Loss of lung volume as well as ground glass opacities and areas of consolidation are evident.\u003c/p\u003e","description":"","filename":"1.jpg","url":"https://assets-eu.researchsquare.com/files/rs-6568124/v1/1655cf6cb3b5adc2d3ddcc61.jpg"},{"id":82375151,"identity":"9a872dfd-9366-48ab-8892-3b07fab4dd28","added_by":"auto","created_at":"2025-05-09 14:27:22","extension":"jpg","order_by":2,"title":"Figure 2","display":"","copyAsset":false,"role":"figure","size":169420,"visible":true,"origin":"","legend":"\u003cp\u003eThe overall survival (OS) and non-relapse mortality (NRM) of the whole cohort (Panels A and B) and stratified by pulmonary manifestations of engraftment syndrome (PES) (Panels C and D) are shown.\u003c/p\u003e","description":"","filename":"2.jpg","url":"https://assets-eu.researchsquare.com/files/rs-6568124/v1/4a5bd1bca4850e8c0cea1d21.jpg"},{"id":92146552,"identity":"724cf226-8066-4b94-b4ad-41636400fcc2","added_by":"auto","created_at":"2025-09-25 07:10:58","extension":"pdf","order_by":0,"title":"","display":"","copyAsset":false,"role":"manuscript-pdf","size":2419216,"visible":true,"origin":"","legend":"","description":"","filename":"manuscript.pdf","url":"https://assets-eu.researchsquare.com/files/rs-6568124/v1/0324eb9a-1e74-49ba-b17f-18cbead4fa99.pdf"}],"financialInterests":"The authors have declared there is \u003cb\u003eNO\u003c/b\u003e conflict of interest to disclose.","formattedTitle":"Pulmonary manifestations during neutrophil engraftment in recipients of allogeneic hematopoietic cell transplantation for myelofibrosis","fulltext":[{"header":"Introduction","content":"\u003cp\u003eAllogeneic hematopoietic cell transplantation (alloHCT) is the only potentially curative modality for primary and secondary myelofibrosis due to other myeloproliferative neoplasms (MPN).[\u003cspan citationid=\"CR1\" class=\"CitationRef\"\u003e1\u003c/span\u003e] Although alloHCT is associated with favorable long-term outcomes, there is high non-relapse mortality (NRM) post-transplant which could be as high as 35%.[\u003cspan citationid=\"CR2\" class=\"CitationRef\"\u003e2\u003c/span\u003e] This relatively high NRM is likely contributed by advanced age, comorbid conditions, and organ dysfunction that frequently exists in these patients [\u003cspan citationid=\"CR3\" class=\"CitationRef\"\u003e3\u003c/span\u003e].\u003c/p\u003e \u003cp\u003eEngraftment syndrome (ES) is a clinical condition characterized by fever, skin rash, pulmonary infiltrates, weight gain, hepatic and/or renal dysfunction, and, in rare cases, encephalopathy. It typically arises around the time of neutrophil engraftment and can carry a significant risk of multi-organ failure and even death.[\u003cspan additionalcitationids=\"CR5\" citationid=\"CR4\" class=\"CitationRef\"\u003e4\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR6\" class=\"CitationRef\"\u003e6\u003c/span\u003e] Although diagnostic criteria for ES have been proposed, it remains a diagnosis of exclusion, and its reported incidence varies widely due to the lack of universally accepted definitions. In the literature, the incidence of ES ranges from 7\u0026ndash;90% depending on the study[\u003cspan citationid=\"CR7\" class=\"CitationRef\"\u003e7\u003c/span\u003e] ES has been associated with adverse outcomes following hematopoietic cell transplantation (HCT). In a cohort of 927 pediatric patients undergoing alloHCT, Chang et al. reported a significantly higher incidence of grade 2\u0026ndash;4 acute graft-versus-host disease (75% vs. 34%), increased 2-year non-relapse mortality (38% vs. 19%), and lower overall survival at two years (38% vs. 54%) among those who developed ES compared to those who did not (P\u0026thinsp;\u0026lt;\u0026thinsp;0.001) [\u003cspan citationid=\"CR8\" class=\"CitationRef\"\u003e8\u003c/span\u003e] The variability in ES incidence may be influenced by differences in patient populations, transplant characteristics, and underlying disease biology. While the exact pathophysiology remains unclear, inflammatory cytokine release is believed to play a central role, leading to capillary leak, systemic symptoms, and organ dysfunction.[\u003cspan citationid=\"CR4\" class=\"CitationRef\"\u003e4\u003c/span\u003e, \u003cspan citationid=\"CR7\" class=\"CitationRef\"\u003e7\u003c/span\u003e]\u003c/p\u003e \u003cp\u003eIn patients with myelofibrosis undergoing allogeneic hematopoietic cell transplantation (alloHCT), we have observed prominent pulmonary manifestations emerging during neutrophil engraftment, characterized by pulmonary infiltrates with or without associated hypoxemia. This clinical presentation may be related to pulmonary extramedullary hematopoiesis (EMH), a phenomenon well-documented in patients with myelofibrosis. [\u003cspan citationid=\"CR9\" class=\"CitationRef\"\u003e9\u003c/span\u003e, \u003cspan citationid=\"CR10\" class=\"CitationRef\"\u003e10\u003c/span\u003e]. Therefore, we aimed to further characterize this engraftment-related pulmonary complication in myelofibrosis and assess its association with pre-transplant patient and disease characteristics, as well as its impact on transplant outcomes. Previously, we reported on the prevalence of pulmonary arterial hypertension (PAH) in myelofibrosis and its association with adverse outcomes following alloHCT [\u003cspan citationid=\"CR11\" class=\"CitationRef\"\u003e11\u003c/span\u003e]. Accordingly, we also sought to investigate whether these pulmonary manifestations were associated with pre-transplant pulmonary assessments, with a particular focus on pulmonary arterial hypertension (PAH).\u003c/p\u003e"},{"header":"Methods","content":"\u003cdiv id=\"Sec3\" class=\"Section2\"\u003e \u003ch2\u003ePatients\u003c/h2\u003e \u003cp\u003e This study was approved by the Institutional Review Board of City of Hope Medical Center. Using our institutional transplant database, we identified 83 patients with primary or secondary myelofibrosis who underwent allogeneic hematopoietic cell transplantation (alloHCT) between 2015 and 2020. Comprehensive data were collected from medical records, including patient demographics, disease characteristics, disease status at the time of transplant, molecular mutations, transplant-related variables, and clinical outcomes.\u003c/p\u003e \u003c/div\u003e\n\u003ch3\u003eDefinition of engraftment syndrome\u003c/h3\u003e\n\u003cp\u003ePulmonary manifestations of engraftment were defined as the new onset of pulmonary opacities\u0026mdash;occurring within 96 hours before or after neutrophil engraftment\u0026mdash;in the absence of infection, fluid overload, or left ventricular dysfunction, with or without accompanying hypoxemia. All included patients had documented neutrophil engraftment following stem cell infusion. Additional clinical features consistent with engraftment syndrome were recorded, including non-infectious fever, erythematous rash not attributed to graft-versus-host disease (GvHD), hepatic dysfunction, acute kidney injury, and encephalopathy.\u003c/p\u003e \u003cdiv id=\"Sec5\" class=\"Section2\"\u003e \u003ch2\u003eStatistical analysis\u003c/h2\u003e \u003cp\u003eDescriptive statistics were used to summarize baseline demographic, disease-related, and transplant characteristics. Associations between baseline variables and the occurrence of pulmonary manifestations were evaluated using Fisher\u0026rsquo;s exact test for univariate analysis and exact logistic regression models for multivariable analysis. Hematopoietic cell transplantation (HCT) outcomes stratified by the presence or absence of pulmonary complications during engraftment were assessed using Kaplan-Meier survival curves and log-rank tests for overall survival (OS), and cumulative incidence functions with Gray\u0026rsquo;s test for non-relapse mortality (NRM) and engraftment endpoints. All statistical tests were two-sided, with a significance threshold of P\u0026thinsp;\u0026lt;\u0026thinsp;0.05.\u003c/p\u003e \u003c/div\u003e"},{"header":"Results","content":"\u003cdiv id=\"Sec7\" class=\"Section2\"\u003e \u003ch2\u003ePatient demographics and baseline characteristics\u003c/h2\u003e \u003cp\u003eOf the 83 patients included in this study, 49% had primary myelofibrosis (PMF), while 51% had secondary MF arising from another myeloproliferative neoplasm (MPN). The median age was 62 years (range, 55\u0026ndash;68), and the majority were male (n\u0026thinsp;=\u0026thinsp;53, 64%). The JAK2 V617F mutation was identified in 65% of patients (n\u0026thinsp;=\u0026thinsp;54). Prior to undergoing alloHCT, 61% (n\u0026thinsp;=\u0026thinsp;51) had received ruxolitinib therapy. The median spleen size was 20 cm (range, 16\u0026ndash;23 cm), and more than 90% of patients exhibited\u0026thinsp;\u0026ge;\u0026thinsp;MF2 grade bone marrow fibrosis. Detailed patient characteristics are summarized in \u003cb\u003eTable\u0026nbsp;1\u003c/b\u003e.\u003c/p\u003e\u003ctable border=\"0\" cellspacing=\"0\" cellpadding=\"0\"\u003e\n \u003cthead\u003e\n \u003ctr\u003e\n \u003ctd colspan=\"2\" valign=\"bottom\" style=\"width: 99.2216%;\"\u003e\n \u003cp\u003e\u003cstrong\u003eTable 1. Patient and HCT characteristics\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"bottom\" style=\"width: 75.3128%;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"bottom\" style=\"width: 23.9088%;\"\u003e\n \u003cp\u003eTotal (N=83)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003c/thead\u003e\n \u003ctbody\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 75.3128%;\"\u003e\n \u003cp\u003e\u003cstrong\u003eAge\u0026nbsp;at\u0026nbsp;HCT,\u0026nbsp;years\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 23.9088%;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 75.3128%;\"\u003e\n \u003cp\u003e\u0026nbsp; \u0026nbsp; Median\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 23.9088%;\"\u003e\n \u003cp\u003e62\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 75.3128%;\"\u003e\n \u003cp\u003e\u0026nbsp; \u0026nbsp; Interquartile range\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 23.9088%;\"\u003e\n \u003cp\u003e55,\u0026nbsp;68\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 75.3128%;\"\u003e\n \u003cp\u003e\u0026nbsp; \u0026nbsp; Range\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 23.9088%;\"\u003e\n \u003cp\u003e(17-75)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 75.3128%;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 23.9088%;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 75.3128%;\"\u003e\n \u003cp\u003e\u003cstrong\u003eRecipient\u0026nbsp;sex\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 23.9088%;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 75.3128%;\"\u003e\n \u003cp\u003e\u0026nbsp; \u0026nbsp; Male\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 23.9088%;\"\u003e\n \u003cp\u003e53\u0026nbsp;(63.9%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 75.3128%;\"\u003e\n \u003cp\u003e\u0026nbsp; \u0026nbsp; Female\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 23.9088%;\"\u003e\n \u003cp\u003e30\u0026nbsp;(36.1%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 75.3128%;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 23.9088%;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 75.3128%;\"\u003e\n \u003cp\u003e\u003cstrong\u003eKarnofsky\u0026nbsp;performance\u0026nbsp;status\u0026nbsp;%\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 23.9088%;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 75.3128%;\"\u003e\n \u003cp\u003e\u0026nbsp; \u0026nbsp; Missing\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 23.9088%;\"\u003e\n \u003cp\u003e3\u0026nbsp;(3.6%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 75.3128%;\"\u003e\n \u003cp\u003e\u0026nbsp; \u0026nbsp; 70\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 23.9088%;\"\u003e\n \u003cp\u003e6\u0026nbsp;(7.2%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 75.3128%;\"\u003e\n \u003cp\u003e\u0026nbsp; \u0026nbsp; 80\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 23.9088%;\"\u003e\n \u003cp\u003e31\u0026nbsp;(37.3%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 75.3128%;\"\u003e\n \u003cp\u003e\u0026nbsp; \u0026nbsp; 90\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 23.9088%;\"\u003e\n \u003cp\u003e35\u0026nbsp;(42.2%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 75.3128%;\"\u003e\n \u003cp\u003e\u0026nbsp; \u0026nbsp; 100\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 23.9088%;\"\u003e\n \u003cp\u003e8\u0026nbsp;(9.6%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 75.3128%;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 23.9088%;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 75.3128%;\"\u003e\n \u003cp\u003e\u0026nbsp; \u0026nbsp; 80-100\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 23.9088%;\"\u003e\n \u003cp\u003e74\u0026nbsp;(89.2%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 75.3128%;\"\u003e\n \u003cp\u003e\u0026nbsp; \u0026nbsp; \u0026lt;80\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 23.9088%;\"\u003e\n \u003cp\u003e6\u0026nbsp;(7.2%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 75.3128%;\"\u003e\n \u003cp\u003e\u0026nbsp; \u0026nbsp; Unknown\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 23.9088%;\"\u003e\n \u003cp\u003e3\u0026nbsp;(3.6%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 75.3128%;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 23.9088%;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 75.3128%;\"\u003e\n \u003cp\u003e\u003cstrong\u003eHCT\u0026nbsp;Comorbidity\u0026nbsp;Index\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 23.9088%;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 75.3128%;\"\u003e\n \u003cp\u003e\u0026nbsp; \u0026nbsp; Median\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 23.9088%;\"\u003e\n \u003cp\u003e2\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 75.3128%;\"\u003e\n \u003cp\u003e\u0026nbsp; \u0026nbsp; Interquartile range\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 23.9088%;\"\u003e\n \u003cp\u003e0,\u0026nbsp;3\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 75.3128%;\"\u003e\n \u003cp\u003e\u0026nbsp; \u0026nbsp; Range\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 23.9088%;\"\u003e\n \u003cp\u003e(0-7)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 75.3128%;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 23.9088%;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 75.3128%;\"\u003e\n \u003cp\u003e\u0026nbsp; \u0026nbsp; 0\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 23.9088%;\"\u003e\n \u003cp\u003e21\u0026nbsp;(25.3%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 75.3128%;\"\u003e\n \u003cp\u003e\u0026nbsp; \u0026nbsp; 1-2\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 23.9088%;\"\u003e\n \u003cp\u003e24\u0026nbsp;(28.9%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 75.3128%;\"\u003e\n \u003cp\u003e\u0026nbsp; \u0026nbsp; \u0026ge;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 23.9088%;\"\u003e\n \u003cp\u003e34\u0026nbsp;(41%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 75.3128%;\"\u003e\n \u003cp\u003e\u0026nbsp; \u0026nbsp; Unknown\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 23.9088%;\"\u003e\n \u003cp\u003e4\u0026nbsp;(4.8%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 75.3128%;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 23.9088%;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 75.3128%;\"\u003e\n \u003cp\u003e\u003cstrong\u003ePrimary MF\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 23.9088%;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 75.3128%;\"\u003e\n \u003cp\u003e\u0026nbsp; \u0026nbsp; Yes\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 23.9088%;\"\u003e\n \u003cp\u003e41\u0026nbsp;(49.4%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 75.3128%;\"\u003e\n \u003cp\u003e\u0026nbsp; \u0026nbsp; No\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 23.9088%;\"\u003e\n \u003cp\u003e42\u0026nbsp;(50.6%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 75.3128%;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 23.9088%;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 75.3128%;\"\u003e\n \u003cp\u003e\u003cstrong\u003eJAK2 mutation\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 23.9088%;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 75.3128%;\"\u003e\n \u003cp\u003e\u0026nbsp; \u0026nbsp; Yes\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 23.9088%;\"\u003e\n \u003cp\u003e54\u0026nbsp;(65.1%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 75.3128%;\"\u003e\n \u003cp\u003e\u0026nbsp; \u0026nbsp; No\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 23.9088%;\"\u003e\n \u003cp\u003e29\u0026nbsp;(34.9%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 75.3128%;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 23.9088%;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 75.3128%;\"\u003e\n \u003cp\u003e\u003cstrong\u003eDegree\u0026nbsp;of\u0026nbsp;marrow fibrosis\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 23.9088%;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 75.3128%;\"\u003e\n \u003cp\u003e\u0026nbsp; \u0026nbsp; Missing\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 23.9088%;\"\u003e\n \u003cp\u003e2\u0026nbsp;(2.4%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 75.3128%;\"\u003e\n \u003cp\u003e\u0026nbsp; \u0026nbsp; 1+\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 23.9088%;\"\u003e\n \u003cp\u003e6\u0026nbsp;(7.2%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 75.3128%;\"\u003e\n \u003cp\u003e\u0026nbsp; \u0026nbsp; 2+\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 23.9088%;\"\u003e\n \u003cp\u003e33\u0026nbsp;(39.8%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 75.3128%;\"\u003e\n \u003cp\u003e\u0026nbsp; \u0026nbsp; 3+\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 23.9088%;\"\u003e\n \u003cp\u003e42\u0026nbsp;(50.6%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 75.3128%;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 23.9088%;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 75.3128%;\"\u003e\n \u003cp\u003e\u003cstrong\u003eRuxolitinib therapy\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 23.9088%;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 75.3128%;\"\u003e\n \u003cp\u003e\u0026nbsp; \u0026nbsp; Yes\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 23.9088%;\"\u003e\n \u003cp\u003e50\u0026nbsp;(60.2%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 75.3128%;\"\u003e\n \u003cp\u003e\u0026nbsp; \u0026nbsp; No\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 23.9088%;\"\u003e\n \u003cp\u003e33\u0026nbsp;(39.8%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 75.3128%;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 23.9088%;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 75.3128%;\"\u003e\n \u003cp\u003e\u003cstrong\u003ePre\u0026nbsp;HCT\u0026nbsp;EF\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 23.9088%;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 75.3128%;\"\u003e\n \u003cp\u003e\u0026nbsp; \u0026nbsp; N\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 23.9088%;\"\u003e\n \u003cp\u003e81\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 75.3128%;\"\u003e\n \u003cp\u003e\u0026nbsp; \u0026nbsp; Median\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 23.9088%;\"\u003e\n \u003cp\u003e61\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 75.3128%;\"\u003e\n \u003cp\u003e\u0026nbsp; \u0026nbsp; Interquartile range\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 23.9088%;\"\u003e\n \u003cp\u003e60,\u0026nbsp;65\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 75.3128%;\"\u003e\n \u003cp\u003e\u0026nbsp; \u0026nbsp; Range\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 23.9088%;\"\u003e\n \u003cp\u003e(45-69)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 75.3128%;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 23.9088%;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 75.3128%;\"\u003e\n \u003cp\u003e\u003cstrong\u003ePre\u0026nbsp;HCT\u0026nbsp;PASP\u0026nbsp;(mmhg)\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 23.9088%;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 75.3128%;\"\u003e\n \u003cp\u003e\u0026nbsp; \u0026nbsp; N\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 23.9088%;\"\u003e\n \u003cp\u003e79\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 75.3128%;\"\u003e\n \u003cp\u003e\u0026nbsp; \u0026nbsp; Median\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 23.9088%;\"\u003e\n \u003cp\u003e28\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 75.3128%;\"\u003e\n \u003cp\u003e\u0026nbsp; \u0026nbsp; Interquartile range\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 23.9088%;\"\u003e\n \u003cp\u003e20,\u0026nbsp;34\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 75.3128%;\"\u003e\n \u003cp\u003e\u0026nbsp; \u0026nbsp; Range\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 23.9088%;\"\u003e\n \u003cp\u003e(3-74)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 75.3128%;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 23.9088%;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 75.3128%;\"\u003e\n \u003cp\u003e\u003cstrong\u003ePre\u0026nbsp;HCT\u0026nbsp;Spleen\u0026nbsp;Size\u0026nbsp;(cm)\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 23.9088%;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 75.3128%;\"\u003e\n \u003cp\u003e\u0026nbsp; \u0026nbsp; N\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 23.9088%;\"\u003e\n \u003cp\u003e75\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 75.3128%;\"\u003e\n \u003cp\u003e\u0026nbsp; \u0026nbsp; Median\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 23.9088%;\"\u003e\n \u003cp\u003e20\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 75.3128%;\"\u003e\n \u003cp\u003e\u0026nbsp; \u0026nbsp; Interquartile range\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 23.9088%;\"\u003e\n \u003cp\u003e16,\u0026nbsp;23\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 75.3128%;\"\u003e\n \u003cp\u003e\u0026nbsp; \u0026nbsp; Range\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 23.9088%;\"\u003e\n \u003cp\u003e(10-34)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 75.3128%;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 23.9088%;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 75.3128%;\"\u003e\n \u003cp\u003e\u003cstrong\u003eYear\u0026nbsp;of\u0026nbsp;HCT\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 23.9088%;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 75.3128%;\"\u003e\n \u003cp\u003e\u0026nbsp; \u0026nbsp; 2015\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 23.9088%;\"\u003e\n \u003cp\u003e17\u0026nbsp;(20.5%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 75.3128%;\"\u003e\n \u003cp\u003e\u0026nbsp; \u0026nbsp; 2016\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 23.9088%;\"\u003e\n \u003cp\u003e12\u0026nbsp;(14.5%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 75.3128%;\"\u003e\n \u003cp\u003e\u0026nbsp; \u0026nbsp; 2017\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 23.9088%;\"\u003e\n \u003cp\u003e14\u0026nbsp;(16.9%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 75.3128%;\"\u003e\n \u003cp\u003e\u0026nbsp; \u0026nbsp; 2018\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 23.9088%;\"\u003e\n \u003cp\u003e15\u0026nbsp;(18.1%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 75.3128%;\"\u003e\n \u003cp\u003e\u0026nbsp; \u0026nbsp; 2019\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 23.9088%;\"\u003e\n \u003cp\u003e21\u0026nbsp;(25.3%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 75.3128%;\"\u003e\n \u003cp\u003e\u0026nbsp; \u0026nbsp; 2020\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 23.9088%;\"\u003e\n \u003cp\u003e4\u0026nbsp;(4.8%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 75.3128%;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 23.9088%;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 75.3128%;\"\u003e\n \u003cp\u003e\u003cstrong\u003eDonor\u0026nbsp;Type\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 23.9088%;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 75.3128%;\"\u003e\n \u003cp\u003e\u0026nbsp; \u0026nbsp; MRD\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 25.3434%;\"\u003e\n \u003cp\u003e19\u0026nbsp;(22.9%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 75.3128%;\"\u003e\n \u003cp\u003e\u0026nbsp; \u0026nbsp; MUD\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 25.3434%;\"\u003e\n \u003cp\u003e45\u0026nbsp;(54.2%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 75.3128%;\"\u003e\n \u003cp\u003e\u0026nbsp; \u0026nbsp; MMUD\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 25.3434%;\"\u003e\n \u003cp\u003e10\u0026nbsp;(12%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 75.3128%;\"\u003e\n \u003cp\u003e\u0026nbsp; \u0026nbsp; Haplo\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 23.9088%;\"\u003e\n \u003cp\u003e9\u0026nbsp;(10.8%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 75.3128%;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 23.9088%;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 75.3128%;\"\u003e\n \u003cp\u003e\u003cstrong\u003eDonor\u0026nbsp;sex\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 23.9088%;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 75.3128%;\"\u003e\n \u003cp\u003e\u0026nbsp; \u0026nbsp; Male\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 23.9088%;\"\u003e\n \u003cp\u003e60\u0026nbsp;(72.3%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 75.3128%;\"\u003e\n \u003cp\u003e\u0026nbsp; \u0026nbsp; Female\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 23.9088%;\"\u003e\n \u003cp\u003e23\u0026nbsp;(27.7%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 75.3128%;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 23.9088%;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 75.3128%;\"\u003e\n \u003cp\u003e\u003cstrong\u003eFemale\u0026nbsp;donor\u0026nbsp;to\u0026nbsp;male\u0026nbsp;recipient\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 23.9088%;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 75.3128%;\"\u003e\n \u003cp\u003e\u0026nbsp; \u0026nbsp; Yes\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 23.9088%;\"\u003e\n \u003cp\u003e13\u0026nbsp;(15.7%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 75.3128%;\"\u003e\n \u003cp\u003e\u0026nbsp; \u0026nbsp; No\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 23.9088%;\"\u003e\n \u003cp\u003e70\u0026nbsp;(84.3%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 75.3128%;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 23.9088%;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 75.3128%;\"\u003e\n \u003cp\u003e\u003cstrong\u003eDonor age\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 23.9088%;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 75.3128%;\"\u003e\n \u003cp\u003e\u0026nbsp; \u0026nbsp; Median\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 23.9088%;\"\u003e\n \u003cp\u003e36\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 75.3128%;\"\u003e\n \u003cp\u003e\u0026nbsp; \u0026nbsp; Interquartile range\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 23.9088%;\"\u003e\n \u003cp\u003e27,\u0026nbsp;47\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 75.3128%;\"\u003e\n \u003cp\u003e\u0026nbsp; \u0026nbsp; Range\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 23.9088%;\"\u003e\n \u003cp\u003e(18-69)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 75.3128%;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 23.9088%;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 75.3128%;\"\u003e\n \u003cp\u003e\u003cstrong\u003eGraft Source\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 23.9088%;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 75.3128%;\"\u003e\n \u003cp\u003e\u0026nbsp; \u0026nbsp; Bone Marrow\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 23.9088%;\"\u003e\n \u003cp\u003e2\u0026nbsp;(2.4%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 75.3128%;\"\u003e\n \u003cp\u003e\u0026nbsp; \u0026nbsp; Peripheral Blood Stem Cells\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 23.9088%;\"\u003e\n \u003cp\u003e81\u0026nbsp;(97.6%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 75.3128%;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 23.9088%;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 75.3128%;\"\u003e\n \u003cp\u003e\u003cstrong\u003eABO\u0026nbsp;blood\u0026nbsp;group\u0026nbsp;compatibility\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 23.9088%;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 75.3128%;\"\u003e\n \u003cp\u003e\u0026nbsp; \u0026nbsp; ABO compatible\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 23.9088%;\"\u003e\n \u003cp\u003e48\u0026nbsp;(57.8%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 75.3128%;\"\u003e\n \u003cp\u003e\u0026nbsp; \u0026nbsp; Minor mismatch (donor is O)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 23.9088%;\"\u003e\n \u003cp\u003e13\u0026nbsp;(15.7%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 75.3128%;\"\u003e\n \u003cp\u003e\u0026nbsp; \u0026nbsp; Major mismatch (Recipient is O)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 23.9088%;\"\u003e\n \u003cp\u003e15\u0026nbsp;(18.1%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 75.3128%;\"\u003e\n \u003cp\u003e\u0026nbsp; \u0026nbsp; Bidirectional (None are O)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 23.9088%;\"\u003e\n \u003cp\u003e7\u0026nbsp;(8.4%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 75.3128%;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 23.9088%;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 75.3128%;\"\u003e\n \u003cp\u003e\u003cstrong\u003eDonor/Recipient\u0026nbsp;CMV\u0026nbsp;serostatus\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 23.9088%;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 75.3128%;\"\u003e\n \u003cp\u003e\u0026nbsp; \u0026nbsp; D-/R-\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 23.9088%;\"\u003e\n \u003cp\u003e14\u0026nbsp;(16.9%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 75.3128%;\"\u003e\n \u003cp\u003e\u0026nbsp; \u0026nbsp; D-/R+\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 23.9088%;\"\u003e\n \u003cp\u003e29\u0026nbsp;(34.9%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 75.3128%;\"\u003e\n \u003cp\u003e\u0026nbsp; \u0026nbsp; D+/R-\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 23.9088%;\"\u003e\n \u003cp\u003e8\u0026nbsp;(9.6%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 75.3128%;\"\u003e\n \u003cp\u003e\u0026nbsp; \u0026nbsp; D+/R+\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 23.9088%;\"\u003e\n \u003cp\u003e32\u0026nbsp;(38.6%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 75.3128%;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 23.9088%;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 75.3128%;\"\u003e\n \u003cp\u003e\u003cstrong\u003eConditioning\u0026nbsp;regimen\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 23.9088%;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 75.3128%;\"\u003e\n \u003cp\u003e\u0026nbsp; \u0026nbsp; BUSULFAN/CTX\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 23.9088%;\"\u003e\n \u003cp\u003e4\u0026nbsp;(4.8%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 75.3128%;\"\u003e\n \u003cp\u003e\u0026nbsp; \u0026nbsp; FLUDARABINE/BUSULFAN\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 23.9088%;\"\u003e\n \u003cp\u003e1\u0026nbsp;(1.2%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 75.3128%;\"\u003e\n \u003cp\u003e\u0026nbsp; \u0026nbsp; FLUDARABINE/CTX/TBI\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 23.9088%;\"\u003e\n \u003cp\u003e1\u0026nbsp;(1.2%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 75.3128%;\"\u003e\n \u003cp\u003e\u0026nbsp; \u0026nbsp; FLUDARABINE/MELPHALAN\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 23.9088%;\"\u003e\n \u003cp\u003e67\u0026nbsp;(80.7%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 75.3128%;\"\u003e\n \u003cp\u003e\u0026nbsp; \u0026nbsp; FLUDARABINE/MELPHALAN/Ruxolitinib/\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 23.9088%;\"\u003e\n \u003cp\u003e2\u0026nbsp;(2.4%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 75.3128%;\"\u003e\n \u003cp\u003e\u0026nbsp; \u0026nbsp; FLUDARABINE/MELPHALAN/TBI\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 23.9088%;\"\u003e\n \u003cp\u003e7\u0026nbsp;(8.4%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 75.3128%;\"\u003e\n \u003cp\u003e\u0026nbsp; \u0026nbsp; FTBI/FLUDARABINE\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 23.9088%;\"\u003e\n \u003cp\u003e1\u0026nbsp;(1.2%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 75.3128%;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 23.9088%;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 75.3128%;\"\u003e\n \u003cp\u003e\u003cstrong\u003eConditioning Regimen Intensity\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 23.9088%;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 75.3128%;\"\u003e\n \u003cp\u003e\u0026nbsp; \u0026nbsp; Myeloblative\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 23.9088%;\"\u003e\n \u003cp\u003e5\u0026nbsp;(6%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 75.3128%;\"\u003e\n \u003cp\u003e\u0026nbsp; \u0026nbsp; Non-myeloablative/Reduced Intensity\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 23.9088%;\"\u003e\n \u003cp\u003e78\u0026nbsp;(94%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 75.3128%;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 23.9088%;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 75.3128%;\"\u003e\n \u003cp\u003e\u003cstrong\u003eGVHD\u0026nbsp;prophylaxis\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 23.9088%;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 75.3128%;\"\u003e\n \u003cp\u003e\u0026nbsp; \u0026nbsp; CTX/TACROLIMUS/CELLCEPT\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 23.9088%;\"\u003e\n \u003cp\u003e14\u0026nbsp;(16.9%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 75.3128%;\"\u003e\n \u003cp\u003e\u0026nbsp; \u0026nbsp; TACROLIMUS/MTX\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 23.9088%;\"\u003e\n \u003cp\u003e5\u0026nbsp;(6%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 75.3128%;\"\u003e\n \u003cp\u003e\u0026nbsp; \u0026nbsp; TACROLIMUS/MTX/BORTEZOMIB\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 23.9088%;\"\u003e\n \u003cp\u003e1\u0026nbsp;(1.2%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 75.3128%;\"\u003e\n \u003cp\u003e\u0026nbsp; \u0026nbsp; TACROLIMUS/SIROLIMUS\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 23.9088%;\"\u003e\n \u003cp\u003e48\u0026nbsp;(57.8%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 75.3128%;\"\u003e\n \u003cp\u003e\u0026nbsp; \u0026nbsp; TACROLIMUS/SIROLIMUS/MTX\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 23.9088%;\"\u003e\n \u003cp\u003e3\u0026nbsp;(3.6%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 75.3128%;\"\u003e\n \u003cp\u003e\u0026nbsp; \u0026nbsp; TACROLIMUS/SIROLIMUS/OTHER\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 23.9088%;\"\u003e\n \u003cp\u003e1\u0026nbsp;(1.2%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 75.3128%;\"\u003e\n \u003cp\u003e\u0026nbsp; \u0026nbsp; TACROLIMUS/SIROLIMUS/Ruxolitinib\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 23.9088%;\"\u003e\n \u003cp\u003e11\u0026nbsp;(13.3%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003c/tbody\u003e\n\u003c/table\u003e\n\u003cp\u003eHCT= Hematopoietic Cell Transplantation, GVHD= graft versus host disease CMV=cytomegalovirus EF=Ejection fraction, PASP=pulmonary artery systolic pressure\u003c/p\u003e \u003cp\u003e \u003cb\u003eHematopoietic Cell Transplantation\u003c/b\u003e.\u003c/p\u003e \u003cp\u003eThe median Hematopoietic Cell Transplantation\u0026ndash;Comorbidity Index (HCT-CI) score was 2 (range, 0\u0026ndash;7). The most common graft source for alloHCT was a matched unrelated donor (MUD) in 54% of cases, followed by matched related donors (MRD) in 23%, mismatched unrelated donors (MMUD) in 12%, and haploidentical donors in 11%. Mobilized peripheral blood stem cells were utilized in 97.6% of transplants. The majority of patients (83%) received a fludarabine-melphalan conditioning regimen. For graft-versus-host disease (GVHD) prophylaxis, tacrolimus combined with sirolimus was used in 57.8% of patients (n\u0026thinsp;=\u0026thinsp;48). The median CD34\u0026thinsp;+\u0026thinsp;cell dose infused was 6.0 \u0026times; 10⁶ cells/kg (range, 2.49\u0026ndash;12.96), and the median CD3\u0026thinsp;+\u0026thinsp;cell dose was 2.21 \u0026times; 10⁶ cells/kg (range, 0.25\u0026ndash;4.90). Neutrophil engraftment occurred at a median of 20 days, and platelet engraftment at a median of 37 days. Additional transplant-related details are summarized in \u003cb\u003eTable\u0026nbsp;1\u003c/b\u003e.\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec8\" class=\"Section2\"\u003e \u003ch2\u003ePulmonary manifestations of engraftment\u003c/h2\u003e \u003cp\u003ePulmonary infiltrates were observed in 25 patients (30%) at the time of neutrophil engraftment. Radiologic findings included ground-glass opacities, areas of consolidation, and pulmonary nodules. In 18 of these patients (72%), the pulmonary findings were attributed to engraftment-related complications. Eight patients (44%) required admission to the intensive care unit (ICU). Hypoxemia was present in 15 patients (83%), of whom six (40%) required mechanical ventilation. Among the remaining hypoxemic patients, two (13%) required high-flow oxygen, while seven (47%) were managed with low-flow oxygen via nasal cannula (2\u0026ndash;6 L/min). Additional symptoms consistent with engraftment syndrome included fever (33%), diarrhea (33%), and rash (22%). Half of the patients with pulmonary manifestations (n\u0026thinsp;=\u0026thinsp;9) were treated with systemic corticosteroids.\u003c/p\u003e \u003c/div\u003e\n\u003ch3\u003eRisk factors for pulmonary complications during engraftment\u003c/h3\u003e\n\u003cp\u003eThe association between pre-transplant pulmonary parameters and the development of pulmonary complications during engraftment is summarized in Table\u0026nbsp;\u003cspan refid=\"Tab1\" class=\"InternalRef\"\u003e2\u003c/span\u003e. Demographic factors and transplant-related characteristics did not reveal any significant predictors of pulmonary involvement, as detailed in Table\u0026nbsp;\u003cspan refid=\"Tab2\" class=\"InternalRef\"\u003e3\u003c/span\u003e. Pre-transplant chest CT scans were reported as normal in 87% of patients. Among the 18 patients who developed pulmonary manifestations of engraftment, 9 had small pulmonary nodules (\u0026le;\u0026thinsp;5 mm) identified on pre-HCT imaging. Representative CT images from two of these patients are shown in Fig.\u0026nbsp;\u003cspan refid=\"Fig1\" class=\"InternalRef\"\u003e1\u003c/span\u003e.\u003c/p\u003e \u003cp\u003e \u003cdiv class=\"gridtable\"\u003e\u003ctable float=\"Yes\" id=\"Tab1\" border=\"1\"\u003e \u003ccaption language=\"En\"\u003e \u003cdiv class=\"CaptionNumber\"\u003eTable 2\u003c/div\u003e \u003cdiv class=\"CaptionContent\"\u003e \u003cp\u003eAssociation of disease and HCT factors with occurrence of Pulmonary Complications of Engraftment Syndrome (PES)\u003c/p\u003e \u003c/div\u003e \u003c/caption\u003e \u003ccolgroup cols=\"9\"\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c1\" colnum=\"1\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c2\" colnum=\"2\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c3\" colnum=\"3\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c4\" colnum=\"4\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c5\" colnum=\"5\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c6\" colnum=\"6\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c7\" colnum=\"7\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c8\" colnum=\"8\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c9\" colnum=\"9\"\u003e\u003c/div\u003e \u003cthead\u003e \u003ctr\u003e \u003cth align=\"left\" colspan=\"2\" nameend=\"c2\" namest=\"c1\"\u003e\u0026nbsp;\u003c/th\u003e \u003cth align=\"left\" colspan=\"4\" nameend=\"c6\" namest=\"c3\"\u003e \u003cp\u003e\u003cem\u003ePES\u003c/em\u003e\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colspan=\"3\" nameend=\"c9\" namest=\"c7\"\u003e\u0026nbsp;\u003c/th\u003e \u003c/tr\u003e \u003c/thead\u003e \u003ctbody\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e\u003cem\u003eN\u003c/em\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e\u003cem\u003eYes\u003c/em\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e\u003cem\u003eNo\u003c/em\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c7\" namest=\"c6\"\u003e \u003cp\u003e\u003cem\u003eFisher's exact test p value\u003c/em\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e\u003cem\u003eAdjusted OR (95%CI)*\u003c/em\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c9\"\u003e \u003cp\u003e\u003cem\u003eP value*\u003c/em\u003e\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eAge at HCT (years)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e\u0026lt;\u0026thinsp;65\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e44\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e9(20.5%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e35(79.5%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c7\" namest=\"c6\"\u003e \u003cp\u003e0.80\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003eReference\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c9\"\u003e \u003cp\u003e1.00\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e\u0026ge;\u0026thinsp;65\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e39\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e9(23.1%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e30(76.9%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c7\" namest=\"c6\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e0.88(0.24,3.05)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c9\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eSex\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eM\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e53\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e11(20.8%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e42(79.2%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c7\" namest=\"c6\"\u003e \u003cp\u003e0.79\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003eReference\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c9\"\u003e \u003cp\u003e1.00\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eF\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e30\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e7(23.3%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e23(76.7%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c7\" namest=\"c6\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e1.07(0.29,3.74)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c9\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eKPS, %\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e90\u0026ndash;100\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e43\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e10(23.3%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e33(76.7%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c7\" namest=\"c6\"\u003e \u003cp\u003e0.79\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003eReference\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c9\"\u003e \u003cp\u003e1.00\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e\u0026le;\u0026thinsp;80\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e37\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e7(18.9%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e30(81.1%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c7\" namest=\"c6\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e0.86(0.23,3.04)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c9\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eHCT Comorbidity Index\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e0\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e21\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e4(19.0%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e17(81.0%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c7\" namest=\"c6\"\u003e \u003cp\u003e0.62\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003eReference\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c9\"\u003e \u003cp\u003e0.74\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e1\u0026ndash;2\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e25\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e7(28.0%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e18(72.0%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c7\" namest=\"c6\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e1.67(0.28,11.02)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c9\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e\u0026ge;\u0026thinsp;3\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e34\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e6(17.6%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e28(82.4%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c7\" namest=\"c6\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e0.98(0.19,5.71)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c9\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eDonor\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eMatched\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e64\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e13(20.3%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e51(79.7%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c7\" namest=\"c6\"\u003e \u003cp\u003e0.54\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003eReference\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c9\"\u003e \u003cp\u003e0.74\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eMMUD or Haplo\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e19\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e5(26.3%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e14(73.7%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c7\" namest=\"c6\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e1.28(0.28,5.23)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c9\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eFemale to Male HCT\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eNo\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e70\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e16(22.9%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e54(77.1%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c7\" namest=\"c6\"\u003e \u003cp\u003e0.72\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003eReference\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c9\"\u003e \u003cp\u003e0.71\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eYes\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e13\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e2(15.4%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e11(84.6%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c7\" namest=\"c6\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e0.53(0.05,3.00)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c9\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003ePrimary MF\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eYes\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e41\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e8(19.5%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e33(80.5%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c7\" namest=\"c6\"\u003e \u003cp\u003e0.79\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003eReference\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c9\"\u003e \u003cp\u003e0.79\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eNo\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e42\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e10(23.8%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e32(76.2%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c7\" namest=\"c6\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e1.18(0.34,4.17)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c9\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eJAK2 mutation\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eYes\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e54\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e14(25.9%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e40(74.1%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c7\" namest=\"c6\"\u003e \u003cp\u003e0.27\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003eReference\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c9\"\u003e \u003cp\u003e0.16\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eNo\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e29\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e4(13.8%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e25(86.2%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c7\" namest=\"c6\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e0.39(0.08,1.50)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c9\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eDegree of fibrosis (MF grade)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e1\u0026thinsp;+\u0026thinsp;or 2+\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e39\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e9(23.1%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e30(76.9%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c7\" namest=\"c6\"\u003e \u003cp\u003e1.00\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003eReference\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c9\"\u003e \u003cp\u003e1.00\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e3+\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e42\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e9(21.4%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e33(78.6%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c7\" namest=\"c6\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e0.88(0.24,3.24)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c9\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eRuxolitinib use\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eYes\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e50\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e14(28.0%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e36(72.0%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c7\" namest=\"c6\"\u003e \u003cp\u003e0.11\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003eReference\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c9\"\u003e \u003cp\u003e0.099\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eNo\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e33\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e4(12.1%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e29(87.9%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c7\" namest=\"c6\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e0.35(0.07,1.34)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c9\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003ePre\u0026nbsp;HCT\u0026nbsp;EF\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e\u0026le;\u0026thinsp;60\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e40\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e11(27.5%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e29(72.5%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c7\" namest=\"c6\"\u003e \u003cp\u003e0.30\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003eReference\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c9\"\u003e \u003cp\u003e0.77\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e\u0026gt;\u0026thinsp;60\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e41\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e7(17.1%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e34(82.9%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c7\" namest=\"c6\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e0.74(0.20,2.70)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c9\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003ePre\u0026nbsp;BMT\u0026nbsp;PASP\u0026nbsp;(mmHg)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e\u0026le;\u0026thinsp;28\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e43\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e4(9.3%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e39(90.7%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c7\" namest=\"c6\"\u003e \u003cp\u003e0.011\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003eReference\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c9\"\u003e \u003cp\u003e0.011\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e\u0026gt;\u0026thinsp;28\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e36\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e12(33.3%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e24(66.7%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c7\" namest=\"c6\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e4.78(1.26,22.69)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c9\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e\u0026lt;\u0026thinsp;35\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e61\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e9(14.8%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e52(85.2%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c7\" namest=\"c6\"\u003e \u003cp\u003e\u003cb\u003e0.042\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003eReference\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c9\"\u003e \u003cp\u003e0.042\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e\u0026ge;\u0026thinsp;35\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e18\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e7(38.9%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e11(61.1%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c7\" namest=\"c6\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e3.68(1.13,12.00)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c9\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003ePre\u0026nbsp;HCT\u0026nbsp;Spleen\u0026nbsp;Size\u0026nbsp;(cm)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e\u0026lt;\u0026thinsp;20\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e39\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e6(15.4%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e33(84.6%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c7\" namest=\"c6\"\u003e \u003cp\u003e0.26\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003eReference\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c9\"\u003e \u003cp\u003e0.23\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e\u0026ge;\u0026thinsp;20\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e36\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e10(27.8%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e26(72.2%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c7\" namest=\"c6\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e2.21(0.54,9.82)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c9\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003ePre\u0026nbsp;HCT\u0026nbsp;CT\u0026nbsp;chest\u0026nbsp;finding\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eNormal\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e72\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e17(23.6%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e55(76.4%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c7\" namest=\"c6\"\u003e \u003cp\u003e0.44\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003eReference\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c9\"\u003e \u003cp\u003e0.42\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eAbnormal\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e11\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e1(9.1%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e10(90.9%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c7\" namest=\"c6\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e0.29(0.01,2.52)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c9\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003ePre HCT FEV1\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e\u0026ge;\u0026thinsp;80%\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e63\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e11(17.5%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e52(82.5%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c7\" namest=\"c6\"\u003e \u003cp\u003e0.28\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003eReference\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c9\"\u003e \u003cp\u003e0.25\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e\u0026lt;\u0026thinsp;80%\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e15\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e5(33.3%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e10(66.7%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c7\" namest=\"c6\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e2.60(0.50,13.32)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c9\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003ePre HCT FEV1/FVC\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e\u0026ge;\u0026thinsp;70%\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e60\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e13(21.7%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e47(78.3%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c7\" namest=\"c6\"\u003e \u003cp\u003e0.75\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003eReference\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c9\"\u003e \u003cp\u003e1.00\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e\u0026lt;\u0026thinsp;70%\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e18\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e3(16.7%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e15(83.3%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c7\" namest=\"c6\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e0.84(0.08,5.40)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c9\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003ePre HCT DLCO\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e\u0026ge;\u0026thinsp;80%\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e21\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e5(23.8%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e16(76.2%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c7\" namest=\"c6\"\u003e \u003cp\u003e0.76\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003eReference\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c9\"\u003e \u003cp\u003e0.74\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e\u0026lt;\u0026thinsp;80%\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e56\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e11(19.6%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e45(80.4%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c7\" namest=\"c6\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e0.79(0.18,4.10)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c9\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003c/tbody\u003e \u003c/colgroup\u003e \u003ctfoot\u003e \u003ctr\u003e\u003ctd colspan=\"9\"\u003e* Based on exact logistic regression adjusting for Pre HCT pulmonary pressure\u003c/td\u003e\u003c/tr\u003e \u003c/tfoot\u003e \u003c/table\u003e\u003c/div\u003e \u003c/p\u003e \u003cp\u003e \u003cdiv class=\"gridtable\"\u003e\u003ctable float=\"Yes\" id=\"Tab2\" border=\"1\"\u003e \u003ccaption language=\"En\"\u003e \u003cdiv class=\"CaptionNumber\"\u003eTable 3\u003c/div\u003e \u003cdiv class=\"CaptionContent\"\u003e \u003cp\u003eAssociation of patient and HCT characteristics with OS and NRM\u003c/p\u003e \u003c/div\u003e \u003c/caption\u003e \u003ccolgroup cols=\"13\"\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c1\" colnum=\"1\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c2\" colnum=\"2\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c3\" colnum=\"3\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c4\" colnum=\"4\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c5\" colnum=\"5\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c6\" colnum=\"6\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c7\" colnum=\"7\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c8\" colnum=\"8\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c9\" colnum=\"9\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c10\" colnum=\"10\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c11\" colnum=\"11\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c12\" colnum=\"12\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c13\" colnum=\"13\"\u003e\u003c/div\u003e \u003cthead\u003e \u003ctr\u003e \u003cth align=\"left\" colspan=\"3\" nameend=\"c3\" namest=\"c1\"\u003e\u0026nbsp;\u003c/th\u003e \u003cth align=\"left\" colspan=\"5\" nameend=\"c8\" namest=\"c4\"\u003e \u003cp\u003e\u003cem\u003eOverall Survival\u003c/em\u003e\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colspan=\"5\" nameend=\"c13\" namest=\"c9\"\u003e \u003cp\u003e\u003cem\u003eNRM\u003c/em\u003e\u003c/p\u003e \u003c/th\u003e \u003c/tr\u003e \u003ctr\u003e \u003cth align=\"left\" colname=\"c1\"\u003e\u0026nbsp;\u003c/th\u003e \u003cth align=\"left\" colname=\"c2\"\u003e\u0026nbsp;\u003c/th\u003e \u003cth align=\"left\" colname=\"c3\"\u003e \u003cp\u003e\u003cem\u003eN\u003c/em\u003e\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c4\"\u003e \u003cp\u003e\u003cem\u003e1 Yr (95%CI)*\u003c/em\u003e\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c5\"\u003e \u003cp\u003e\u003cem\u003eHR (95%CI)*\u003c/em\u003e\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c6\"\u003e \u003cp\u003e\u003cem\u003eP*\u003c/em\u003e\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c7\"\u003e \u003cp\u003e\u003cem\u003eAdjusted HR (95%CI)\u0026dagger;\u003c/em\u003e\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c8\"\u003e \u003cp\u003e\u003cem\u003eP\u0026dagger;\u003c/em\u003e\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c9\"\u003e \u003cp\u003e\u003cem\u003e100 day (95%CI)*\u003c/em\u003e\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c10\"\u003e \u003cp\u003e\u003cem\u003eHR (95%CI)*\u003c/em\u003e\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c11\"\u003e \u003cp\u003e\u003cem\u003eP*\u003c/em\u003e\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c12\"\u003e \u003cp\u003e\u003cem\u003eAdjusted HR (95%CI) \u0026dagger;\u003c/em\u003e\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c13\"\u003e \u003cp\u003e\u003cem\u003eP\u0026dagger;\u003c/em\u003e\u003c/p\u003e \u003c/th\u003e \u003c/tr\u003e \u003c/thead\u003e \u003ctbody\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eAge at HCT, years\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e\u0026lt;\u0026thinsp;65\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e44\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e0.656(0.494,0.776)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003eReference\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e0.82\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003eReference\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e0.56\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c9\"\u003e \u003cp\u003e0.114(0.041,0.227)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c10\"\u003e \u003cp\u003eReference\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c11\"\u003e \u003cp\u003e0.71\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c12\"\u003e \u003cp\u003eReference\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c13\"\u003e \u003cp\u003e0.67\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e\u0026ge;\u0026thinsp;65\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e39\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e0.615(0.445,0.747)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e1.08(0.55,2.11)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e1.22(0.62,2.40)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c9\"\u003e \u003cp\u003e0.205(0.095,0.344)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c10\"\u003e \u003cp\u003e1.13(0.51,2.51)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c11\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c12\"\u003e \u003cp\u003e1.19(0.53,2.66)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c13\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eSex\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eM\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e53\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e0.657(0.512,0.769)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003eReference\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e0.65\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003eReference\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e0.64\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c9\"\u003e \u003cp\u003e0.132(0.057,0.238)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c10\"\u003e \u003cp\u003eReference\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c11\"\u003e \u003cp\u003e0.81\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c12\"\u003e \u003cp\u003eReference\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c13\"\u003e \u003cp\u003e0.84\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eF\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e30\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e0.600(0.405,0.750)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e1.16(0.59,2.29)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e1.18(0.58,2.41)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c9\"\u003e \u003cp\u003e0.200(0.079,0.360)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c10\"\u003e \u003cp\u003e1.16(0.51,2.61)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c11\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c12\"\u003e \u003cp\u003e1.09(0.47,2.51)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c13\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eKPS, %\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e90\u0026ndash;100\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e43\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e0.647(0.484,0.771)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003eReference\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e0.90\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003eReference\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e0.83\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c9\"\u003e \u003cp\u003e0.186(0.086,0.315)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c10\"\u003e \u003cp\u003eReference\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c11\"\u003e \u003cp\u003e0.31\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c12\"\u003e \u003cp\u003eReference\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c13\"\u003e \u003cp\u003e0.25\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e\u0026le;\u0026thinsp;80\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e37\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e0.649(0.473,0.779)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e0.96(0.48,1.90)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e0.93(0.47,1.85)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c9\"\u003e \u003cp\u003e0.108(0.034,0.233)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c10\"\u003e \u003cp\u003e0.63(0.27,1.48)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c11\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c12\"\u003e \u003cp\u003e0.60(0.25,1.44)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c13\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eHCT Comorbidity Index\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e0\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e21\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e0.571(0.338,0.749)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003eReference\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e0.15\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003eReference\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e0.81\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c9\"\u003e \u003cp\u003e0.238(0.083,0.437)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c10\"\u003e \u003cp\u003eReference\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c11\"\u003e \u003cp\u003e0.53\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c12\"\u003e \u003cp\u003eReference\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c13\"\u003e \u003cp\u003e0.67\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e1\u0026ndash;2\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e25\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e0.513(0.304,0.689)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e0.89(0.40,2.01)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e1.13(0.46,2.79)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c9\"\u003e \u003cp\u003e0.120(0.029,0.280)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c10\"\u003e \u003cp\u003e0.67(0.25,1.79)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c11\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c12\"\u003e \u003cp\u003e0.72(0.26,1.99)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c13\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e\u0026ge;\u0026thinsp;3\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e34\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e0.765(0.584,0.875)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e0.48(0.21,1.13)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e0.84(0.33,2.11)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c9\"\u003e \u003cp\u003e0.147(0.053,0.287)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c10\"\u003e \u003cp\u003e0.60(0.23,1.56)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c11\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c12\"\u003e \u003cp\u003e0.65(0.25,1.71)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c13\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eDonor\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eMatched\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e64\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e0.686(0.556,0.784)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003eReference\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e0.065\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003eReference\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e0.022\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c9\"\u003e \u003cp\u003e0.125(0.058,0.219)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c10\"\u003e \u003cp\u003eReference\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c11\"\u003e \u003cp\u003e0.25\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c12\"\u003e \u003cp\u003eReference\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c13\"\u003e \u003cp\u003e0.27\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eMMUD or Haplo\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e19\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e0.474(0.244,0.673)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e1.92(0.94,3.93)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e2.41(1.13,5.11)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c9\"\u003e \u003cp\u003e0.263(0.092,0.474)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c10\"\u003e \u003cp\u003e1.66(0.68,4.05)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c11\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c12\"\u003e \u003cp\u003e1.66(0.68,4.05)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c13\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eFemale to Male HCT\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eNo\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e70\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e0.627(0.503,0.729)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003eReference\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e0.94\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003eReference\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e0.81\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c9\"\u003e \u003cp\u003e0.157(0.083,0.252)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c10\"\u003e \u003cp\u003eReference\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c11\"\u003e \u003cp\u003e0.77\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c12\"\u003e \u003cp\u003eReference\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c13\"\u003e \u003cp\u003e0.82\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eYes\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e13\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e0.692(0.373,0.872)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e0.96(0.37,2.48)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e1.12(0.43,2.92)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c9\"\u003e \u003cp\u003e0.154(0.022,0.399)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c10\"\u003e \u003cp\u003e1.15(0.41,3.27)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c11\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c12\"\u003e \u003cp\u003e1.13(0.40,3.20)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c13\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003ePrimary MF\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eYes\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e41\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e0.707(0.543,0.822)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003eReference\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e0.34\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003eReference\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e0.75\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c9\"\u003e \u003cp\u003e0.171(0.074,0.301)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c10\"\u003e \u003cp\u003eReference\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c11\"\u003e \u003cp\u003e0.51\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c12\"\u003e \u003cp\u003eReference\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c13\"\u003e \u003cp\u003e0.44\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eNo\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e42\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e0.568(0.405,0.702)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e1.37(0.70,2.67)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e1.12(0.56,2.23)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c9\"\u003e \u003cp\u003e0.143(0.057,0.266)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c10\"\u003e \u003cp\u003e1.34(0.60,2.99)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c11\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c12\"\u003e \u003cp\u003e1.38(0.61,3.10)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c13\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eJAK2 mutation\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eYes\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e54\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e0.630(0.487,0.743)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003eReference\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e0.99\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003eReference\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e0.66\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c9\"\u003e \u003cp\u003e0.167(0.081,0.278)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c10\"\u003e \u003cp\u003eReference\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c11\"\u003e \u003cp\u003e0.52\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c12\"\u003e \u003cp\u003eReference\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c13\"\u003e \u003cp\u003e0.57\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eNo\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e29\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e0.651(0.448,0.795)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e1.00(0.50,1.98)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e1.18(0.56,2.50)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c9\"\u003e \u003cp\u003e0.138(0.042,0.289)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c10\"\u003e \u003cp\u003e0.78(0.34,1.78)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c11\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c12\"\u003e \u003cp\u003e0.79(0.34,1.81)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c13\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eDegree of marrow fibrosis\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e1\u0026thinsp;+\u0026thinsp;or 2+\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e39\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e0.615(0.445,0.747)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003eReference\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e0.34\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003eReference\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e0.30\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c9\"\u003e \u003cp\u003e0.205(0.095,0.344)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c10\"\u003e \u003cp\u003eReference\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c11\"\u003e \u003cp\u003e0.35\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c12\"\u003e \u003cp\u003eReference\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c13\"\u003e \u003cp\u003e0.45\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e3+\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e42\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e0.687(0.522,0.805)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e0.72(0.36,1.43)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e0.68(0.33,1.41)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c9\"\u003e \u003cp\u003e0.119(0.043,0.237)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c10\"\u003e \u003cp\u003e0.65(0.28,1.52)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c11\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c12\"\u003e \u003cp\u003e0.71(0.29,1.72)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c13\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eRuxolitinib therapy\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eYes\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e50\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e0.640(0.491,0.756)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003eReference\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e0.78\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003eReference\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e0.46\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c9\"\u003e \u003cp\u003e0.160(0.074,0.275)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c10\"\u003e \u003cp\u003eReference\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c11\"\u003e \u003cp\u003e0.68\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c12\"\u003e \u003cp\u003eReference\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c13\"\u003e \u003cp\u003e0.64\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eNo\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e33\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e0.632(0.442,0.772)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e1.10(0.56,2.14)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e1.32(0.63,2.77)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c9\"\u003e \u003cp\u003e0.152(0.054,0.295)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c10\"\u003e \u003cp\u003e1.21(0.55,2.66)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c11\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c12\"\u003e \u003cp\u003e1.21(0.55,2.67)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c13\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003ePre\u0026nbsp;HCT\u0026nbsp;EF\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e\u0026le;\u0026thinsp;60\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e40\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e0.721(0.553,0.835)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003eReference\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e0.87\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003eReference\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e0.65\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c9\"\u003e \u003cp\u003e0.125(0.045,0.248)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c10\"\u003e \u003cp\u003eReference\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c11\"\u003e \u003cp\u003e0.50\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c12\"\u003e \u003cp\u003eReference\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c13\"\u003e \u003cp\u003e0.55\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e\u0026gt;\u0026thinsp;60\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e41\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e0.585(0.420,0.718)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e1.06(0.53,2.09)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e0.84(0.41,1.74)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c9\"\u003e \u003cp\u003e0.195(0.090,0.329)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c10\"\u003e \u003cp\u003e1.32(0.57,3.05)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c11\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c12\"\u003e \u003cp\u003e1.30(0.56,2.99)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c13\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003ePre\u0026nbsp;HCT PASP(mmHg)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e\u0026le;\u0026thinsp;28\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e43\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e0.674(0.513,0.793)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003eReference\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e0.46\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003eReference\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e0.10\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c9\"\u003e \u003cp\u003e0.140(0.056,0.261)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c10\"\u003e \u003cp\u003eReference\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c11\"\u003e \u003cp\u003e0.81\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c12\"\u003e \u003cp\u003eReference\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c13\"\u003e \u003cp\u003e0.83\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e\u0026gt;\u0026thinsp;28\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e36\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e0.636(0.457,0.770)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e1.28(0.64,2.57)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e1.88(0.88,4.00)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c9\"\u003e \u003cp\u003e0.194(0.084,0.338)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c10\"\u003e \u003cp\u003e1.14(0.50,2.61)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c11\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c12\"\u003e \u003cp\u003e1.09(0.48,2.47)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c13\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e\u0026lt;\u0026thinsp;35\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e61\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e0.719(0.587,0.815)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003eReference\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e\u003cb\u003e0.007\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003eReference\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e\u003cb\u003e\u0026lt;\u0026thinsp;0.001\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c9\"\u003e \u003cp\u003e0.115(0.050,0.209)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c10\"\u003e \u003cp\u003eReference\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c11\"\u003e \u003cp\u003e\u003cb\u003e0.031\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c12\"\u003e \u003cp\u003eReference\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c13\"\u003e \u003cp\u003e\u003cb\u003e0.040\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e\u0026ge;\u0026thinsp;35\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e18\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e0.444(0.216,0.651)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e2.58(1.24,5.40)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e4.68(1.93,11.37)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c9\"\u003e \u003cp\u003e0.333(0.131,0.552)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c10\"\u003e \u003cp\u003e2.55(1.07,6.08)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c11\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c12\"\u003e \u003cp\u003e2.42(1.04,5.62)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c13\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003ePre\u0026nbsp;HCT\u0026nbsp;Spleen\u0026nbsp;Size\u0026nbsp;(cm)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e\u0026lt;\u0026thinsp;20\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e39\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e0.872(0.719,0.945)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003eReference\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e\u0026lt;\u0026thinsp;0.001\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003eReference\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e\u0026lt;\u0026thinsp;0.001\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c9\"\u003e \u003cp\u003e0.103(0.032,0.222)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c10\"\u003e \u003cp\u003eReference\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c11\"\u003e \u003cp\u003e0.083\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c12\"\u003e \u003cp\u003eReference\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c13\"\u003e \u003cp\u003e0.094\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e\u0026ge;\u0026thinsp;20\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e36\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e0.444(0.280,0.596)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e3.70(1.67,8.22)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e4.14(1.83,9.36)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c9\"\u003e \u003cp\u003e0.194(0.084,0.338)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c10\"\u003e \u003cp\u003e2.18(0.88,5.39)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c11\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c12\"\u003e \u003cp\u003e2.17(0.88,5.38)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c13\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003ePre\u0026nbsp;HCT CT\u0026nbsp;chest\u0026nbsp;finding\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eNormal\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e72\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e0.651(0.528,0.749)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003eReference\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e0.42\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003eReference\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e0.19\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c9\"\u003e \u003cp\u003e0.139(0.071,0.229)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c10\"\u003e \u003cp\u003eReference\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c11\"\u003e \u003cp\u003e0.47\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c12\"\u003e \u003cp\u003eReference\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c13\"\u003e \u003cp\u003e0.60\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eAbnormal\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e11\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e0.545(0.229,0.780)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e1.42(0.59,3.44)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e1.84(0.75,4.55)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c9\"\u003e \u003cp\u003e0.273(0.058,0.552)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c10\"\u003e \u003cp\u003e1.47(0.50,4.33)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c11\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c12\"\u003e \u003cp\u003e1.36(0.44,4.22)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c13\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003ePre HCT FEV1\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e\u0026ge;\u0026thinsp;80%\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e63\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e0.635(0.504,0.740)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003eReference\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e0.66\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003eReference\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e0.96\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c9\"\u003e \u003cp\u003e0.175(0.093,0.278)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c10\"\u003e \u003cp\u003eReference\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c11\"\u003e \u003cp\u003e0.17\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c12\"\u003e \u003cp\u003eReference\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c13\"\u003e \u003cp\u003e0.21\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e\u0026lt;\u0026thinsp;80%\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e15\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e0.660(0.365,0.843)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e0.82(0.34,1.99)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e1.03(0.41,2.54)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c9\"\u003e \u003cp\u003e0.067(0.004,0.270)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c10\"\u003e \u003cp\u003e0.38(0.09,1.60)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c11\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c12\"\u003e \u003cp\u003e0.39(0.09,1.68)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c13\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003ePre HCT FEV1/FVC\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e\u0026ge;\u0026thinsp;70%\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e60\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e0.631(0.496,0.740)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003eReference\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e0.45\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003eReference\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e0.80\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c9\"\u003e \u003cp\u003e0.150(0.073,0.252)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c10\"\u003e \u003cp\u003eReference\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c11\"\u003e \u003cp\u003e0.67\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c12\"\u003e \u003cp\u003eReference\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c13\"\u003e \u003cp\u003e0.97\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e\u0026lt;\u0026thinsp;70%\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e18\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e0.667(0.404,0.834)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e0.72(0.30,1.73)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e0.88(0.35,2.27)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c9\"\u003e \u003cp\u003e0.167(0.039,0.372)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c10\"\u003e \u003cp\u003e0.78(0.26,2.29)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c11\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c12\"\u003e \u003cp\u003e0.98(0.32,3.03)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c13\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003ePre HCT DLCO\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e\u0026ge;\u0026thinsp;80%\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e21\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e0.714(0.472,0.860)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003eReference\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e0.24\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003eReference\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e0.064\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c9\"\u003e \u003cp\u003e0.048(0.003,0.202)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c10\"\u003e \u003cp\u003eReference\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c11\"\u003e \u003cp\u003e0.37\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c12\"\u003e \u003cp\u003eReference\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c13\"\u003e \u003cp\u003e0.39\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e\u0026lt;\u0026thinsp;80%\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e56\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e0.624(0.484,0.736)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e1.68(0.69,4.08)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e2.36(0.95,5.87)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c9\"\u003e \u003cp\u003e0.196(0.104,0.310)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c10\"\u003e \u003cp\u003e1.66(0.58,4.73)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c11\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c12\"\u003e \u003cp\u003e1.59(0.55,4.58)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c13\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003ePES\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eNo\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e65\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e0.677(0.549,0.776)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003eReference\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e0.062\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003eReference\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e0.074\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c9\"\u003e \u003cp\u003e0.138(0.068,0.234)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c10\"\u003e \u003cp\u003eReference\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c11\"\u003e \u003cp\u003e0.26\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c12\"\u003e \u003cp\u003eReference\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c13\"\u003e \u003cp\u003e0.26\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eYes\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e18\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e0.500(0.259,0.701)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e1.94(0.95,3.96)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e1.93(0.94,3.97)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c9\"\u003e \u003cp\u003e0.222(0.065,0.436)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c10\"\u003e \u003cp\u003e1.65(0.70,3.89)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c11\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c12\"\u003e \u003cp\u003e1.63(0.70,3.83)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c13\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003c/tbody\u003e \u003c/colgroup\u003e \u003ctfoot\u003e \u003ctr\u003e\u003ctd colspan=\"13\"\u003e* based on univariate analysis, log-rank test for OS, and Gray\u0026rsquo;s test for NRM PES: Pulmonary complications of engraftment syndrome\u003c/td\u003e\u003c/tr\u003e \u003ctr\u003e\u003ctd colspan=\"13\"\u003e\u0026dagger; Based on multivariable Cox regression model for OS adjusting for donor type and pre BMT spleen size, and Fine and Gray regression model for NRM adjusting for donor type.\u003c/td\u003e\u003c/tr\u003e \u003c/tfoot\u003e \u003c/table\u003e\u003c/div\u003e \u003c/p\u003e \u003cp\u003e \u003c/p\u003e \u003cp\u003ePulmonary hypertension is a well-recognized comorbidity in patients with myelofibrosis. Pulmonary artery systolic pressure (PASP) measurements were available for 79 patients in this cohort, with a median PASP of 28 mmHg (range, 3\u0026ndash;74 mmHg). Pulmonary arterial hypertension (PAH), defined as PASP\u0026thinsp;\u0026ge;\u0026thinsp;35 mmHg, was identified in 61 patients (77%). The presence of PAH was significantly associated with an increased risk of developing pulmonary complications during engraftment, with an odds ratio of 3.68 (95% CI: 1.13\u0026ndash;12; P\u0026thinsp;=\u0026thinsp;0.04).\u003c/p\u003e \u003cp\u003eAbnormal pulmonary function tests (PFTs) prior to transplant were identified in a substantial proportion of patients: reduced FEV1 (\u0026lt;\u0026thinsp;80%) in 19%, FEV1/FVC ratio\u0026thinsp;\u0026lt;\u0026thinsp;70% in 23%, and decreased DLCO (\u0026lt;\u0026thinsp;80%) in 72%. However, no significant association was observed between these pre-HCT PFT abnormalities and the development of pulmonary complications during engraftment. Specifically, the association between pulmonary complications and FEV1 (95% CI: 0.50\u0026ndash;13.32; P\u0026thinsp;=\u0026thinsp;0.25), FEV1/FVC (95% CI: 0.08\u0026ndash;5.40; P\u0026thinsp;=\u0026thinsp;1.00), and DLCO (95% CI: 0.18\u0026ndash;4.10; P\u0026thinsp;=\u0026thinsp;0.74).\u003c/p\u003e \u003cp\u003eSpleen size was not significantly associated with the development of pulmonary complications during engraftment (P\u0026thinsp;=\u0026thinsp;0.23; 95% CI: 0.54\u0026ndash;9.82). Although neutrophil engraftment occurred earlier in patients who developed pulmonary complications (median 17 days vs. 20 days), this difference did not reach statistical significance (P\u0026thinsp;=\u0026thinsp;0.20).\u003c/p\u003e\n\u003ch3\u003eOverall Survival (OS) and Non-Relapse Mortality (NRM)\u003c/h3\u003e\n\u003cp\u003eThe 12-month and 2-year overall survival (OS) rates were 65% and 63%, respectively. Day 100 mortality was 16%, and the 2-year non-relapse mortality (NRM) rate was 24% \u003cb\u003e(\u003c/b\u003eFig.\u0026nbsp;\u003cspan refid=\"Fig2\" class=\"InternalRef\"\u003e2\u003c/span\u003e). There was no statistically significant difference in OS or NRM between patients who developed pulmonary complications during engraftment and those who did not (HR;1.93, 95% CI 0.94\u0026ndash;3.97, P 0.074 and HR 1.63; 95% CI 0.70\u0026ndash;3.83, P 0.26, respectively).\u003c/p\u003e \u003cp\u003e \u003c/p\u003e \u003cp\u003eThe median ICU stay for patients who developed pulmonary manifestations was 18 days. In multivariate analysis, patients with a pre-HCT pulmonary artery systolic pressure (PASP)\u0026thinsp;\u0026gt;\u0026thinsp;35 mmHg and a spleen size\u0026thinsp;\u0026gt;\u0026thinsp;20 cm had significantly worse overall survival (OS (HR 2.58, 95% CI 1.24\u0026ndash;5.40, P\u0026thinsp;\u0026lt;\u0026thinsp;0.001, and HR 4.14, 95% CI 1.83\u0026ndash;9.36, p\u0026thinsp;\u0026lt;\u0026thinsp;0.001), respectively. Additionally, a PASP\u0026thinsp;\u0026ge;\u0026thinsp;35 mmHg was associated with increased non-relapse mortality (NRM) (HR 2.42, 95% CI: 1.04\u0026ndash;5.62; P\u0026thinsp;=\u0026thinsp;0.040).\u003c/p\u003e \u003cp\u003ePatient, donor, and transplant characteristics and their association with OS and NRM are listed in Table\u0026nbsp;\u003cspan refid=\"Tab2\" class=\"InternalRef\"\u003e3\u003c/span\u003e.\u003c/p\u003e"},{"header":"Discussion","content":"\u003cp\u003eIn this study, we describe a distinct presentation of engraftment syndrome (ES) characterized predominantly by pulmonary infiltrates and respiratory symptoms occurring around the time of neutrophil engraftment in patients undergoing alloHCT for myelofibrosis. Notably, only one-third of these patients exhibited extrapulmonary features typically associated with ES. While this complication did not correlate with decreased overall survival (OS) or increased non-relapse mortality (NRM), it was associated with substantial morbidity. These findings highlight the importance of early recognition and prompt initiation of corticosteroid therapy, which appeared to be effective in managing this syndrome.\u003c/p\u003e \u003cp\u003eAlthough the precise mechanism underlying pulmonary complications during engraftment in myelofibrosis remains unclear, the findings suggest a potential link to pulmonary extramedullary hematopoiesis (EMH) and pulmonary arterial hypertension (PAH)\u0026mdash;both of which are distinctive comorbidities in MF patients undergoing alloHCT. Cardiopulmonary morbidity is frequently observed in this population, with PAH being a particularly common and clinically significant condition. In prior work, we demonstrated that PAH is prevalent among patients with MF and is associated with increased morbidity and mortality following alloHCT. [\u003cspan citationid=\"CR11\" class=\"CitationRef\"\u003e11\u003c/span\u003e]. In that study, PAH was identified in up to 50% of patients prior to transplantation and was associated with significantly worse outcomes, including reduced overall survival (58.9% vs. 88.8%, P\u0026thinsp;=\u0026thinsp;0.025) and increased non-relapse mortality (21.6% vs. 7.1%, P\u0026thinsp;=\u0026thinsp;0.007).[\u003cspan citationid=\"CR11\" class=\"CitationRef\"\u003e11\u003c/span\u003e] In the current cohort, we further validate the association between pre-transplant PAH and adverse transplant outcomes. Moreover, we demonstrate a link between PAH and the development of pulmonary complications during engraftment. Additional contributors to cardiopulmonary morbidity in MF may include hemodynamic alterations related to splenomegaly and portal hypertension, as well as underlying chronic thromboembolic processes.\u003c/p\u003e \u003cp\u003ePulmonary extramedullary hematopoiesis (EMH) has been documented in multiple reports involving patients with myelofibrosis, whether primary or secondary to another myeloproliferative neoplasm (MPN). Evidence of pulmonary EMH has been demonstrated both histologically through biopsy specimens and non-invasively using technetium sulfur colloid scintigraphy. [\u003cspan citationid=\"CR9\" class=\"CitationRef\"\u003e9\u003c/span\u003e, \u003cspan citationid=\"CR10\" class=\"CitationRef\"\u003e10\u003c/span\u003e, \u003cspan citationid=\"CR12\" class=\"CitationRef\"\u003e12\u003c/span\u003e]. Pulmonary EMH has also been implicated in the pathogenesis of PAH in myelofibrosis. Involvement of the pulmonary arteries by EMH, along with associated arteriopathy, has been demonstrated in biopsy specimens, suggesting a potential mechanistic link between EMH and pulmonary vascular remodeling in this setting. [\u003cspan citationid=\"CR9\" class=\"CitationRef\"\u003e9\u003c/span\u003e, \u003cspan citationid=\"CR12\" class=\"CitationRef\"\u003e12\u003c/span\u003e, \u003cspan citationid=\"CR13\" class=\"CitationRef\"\u003e13\u003c/span\u003e]. The observed association between pulmonary manifestations of engraftment and PAH in this study may, in part, be explained by the contribution of pulmonary extramedullary hematopoiesis (EMH) to the development of PAH in myelofibrosis. It is plausible that donor cell engraftment within foci of pulmonary EMH could underlie the pathogenesis of these complications. Routine chest CT imaging appears to be relatively insensitive for detecting pulmonary EMH, especially in the absence of symptoms. In our cohort of 18 patients who developed pulmonary complications during engraftment, only half had small nodules (\u0026lt;\u0026thinsp;1 cm) identified on pre-transplant CT imaging. Given the potential prognostic implications of pulmonary EMH for transplant outcomes, specialized imaging modalities\u0026mdash;such as magnetic resonance imaging (MRI), Indium-111-labeled leukocyte scans, or technetium sulfur colloid scintigraphy\u0026mdash;may be valuable for assessing the extent of pulmonary EMH. This may be particularly useful in MF patients with abnormal pre-transplant chest imaging or known PAH to aid in pre-HCT risk stratification.\u003c/p\u003e \u003cp\u003eA range of radiologic findings has been reported in patients with pulmonary EMH, including ground-glass opacities, areas of consolidation, pulmonary nodules, and pleural effusions [\u003cspan citationid=\"CR9\" class=\"CitationRef\"\u003e9\u003c/span\u003e, \u003cspan additionalcitationids=\"CR14\" citationid=\"CR13\" class=\"CitationRef\"\u003e13\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR15\" class=\"CitationRef\"\u003e15\u003c/span\u003e]. Similar imaging features were observed in our cohort of patients who developed pulmonary complications during engraftment. Representative pre- and post-transplant chest CT images from selected patients in our study who developed pulmonary engraftment syndrome (PES) are shown in Fig.\u0026nbsp;\u003cspan refid=\"Fig2\" class=\"InternalRef\"\u003e2\u003c/span\u003e.\u003c/p\u003e \u003cp\u003eThe use of ruxolitinib in the pre-transplant and immediate post-transplant period may have a favorable impact on mitigating pulmonary manifestations of engraftment. Its immunomodulatory and anti-inflammatory properties could potentially reduce pulmonary inflammation and extramedullary hematopoiesis. Importantly, the use of ruxolitinib during the peritransplant period has been shown to be safe and is not associated with adverse effects on hematopoietic engraftment [\u003cspan citationid=\"CR16\" class=\"CitationRef\"\u003e16\u003c/span\u003e]. Case reports have also documented improvement in pulmonary EMH and associated respiratory parameters following treatment with ruxolitinib, suggesting that it may serve as a beneficial intervention prior to alloHCT to optimize pulmonary function and reduce respiratory complications. [\u003cspan additionalcitationids=\"CR18\" citationid=\"CR17\" class=\"CitationRef\"\u003e17\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR19\" class=\"CitationRef\"\u003e19\u003c/span\u003e]. Both pulmonary arterial hypertension (PAH) and pulmonary extramedullary hematopoiesis (EMH) associated with myelofibrosis have been shown to improve following successful alloHCT [\u003cspan citationid=\"CR11\" class=\"CitationRef\"\u003e11\u003c/span\u003e, \u003cspan citationid=\"CR14\" class=\"CitationRef\"\u003e14\u003c/span\u003e] In our study, the occurrence of pulmonary complications during engraftment was not associated with increased non-relapse mortality (NRM), and all affected patients were successfully managed with supportive care and/or corticosteroids. Although a definitive diagnosis requires exclusion of infectious etiologies, increased awareness of this clinical entity may facilitate earlier initiation of corticosteroid therapy, potentially preventing respiratory deterioration and associated morbidity during the immediate post-transplant period. Early recognition may also help avoid unnecessary invasive procedures, such as lung biopsy, and a trial of empiric corticosteroids should be considered once infections have been ruled out through bronchoalveolar lavage. Given the observed association between PAH and pulmonary complications during engraftment, patients with pre-existing PAH should be closely monitored during the engraftment phase for early signs of this syndrome.\u003c/p\u003e"},{"header":"Declarations","content":" \u003cdiv id=\"Sec12\" class=\"Section2\"\u003e \u003ch2\u003eAuthorship Statement\u003c/h2\u003e \u003cp\u003eV.P. developed the study concept. S.O. and I.A. conducted the study and were responsible for data collection. D.S. assisted with data acquisition. D.Y. performed the statistical analysis. S.R. reviewed and interpreted the imaging studies. V.P., S.O., and I.A. drafted the initial version of the manuscript. All authors contributed intellectual input and participated in the critical revision and final approval of the manuscript.\u003c/p\u003e \u003c/div\u003e\u003cp\u003e \u003ch2\u003eConflicts of interest\u003c/h2\u003e \u003cp\u003eHA and MAM have received research support from Incyte. The remaining authors have no relevant conflicts of interest to declare.\u003c/p\u003e \u003c/p\u003e"},{"header":"References","content":"\u003col\u003e\n\u003cli\u003eAli H, Pullarkat V, Snyder D. Biology and Current Treatment of Myeloproliferative Neoplasms. Cancer Treat Res. 2021;181:151-165. doi:10.1007/978-3-030-78311-2_9\u003c/li\u003e\n\u003cli\u003eChoudhary D, Doval D, Khandelwal V, Setia R, Handoo A. Allogeneic stem cell transplant for myelofibrosis- A retrospective single-center study. Blood Cell Ther. 2023;6:5-10. Published 2023 Feb 10. doi:10.31547/bct-2022-003\u003c/li\u003e\n\u003cli\u003eAcosta-Medina AA, Baranwal A, Johnson IM, et al. Comparison of Pretransplantation Prediction Models for Nonrelapse Mortality in Patients with Myelofibrosis Undergoing Allogeneic Stem Cell Transplantation. Transplant Cell Ther. 2023;29 :360.e1-360.e8. doi:10.1016/j.jtct.2023.02.002\u003c/li\u003e\n\u003cli\u003eSpitzer TR. Engraftment syndrome following hematopoietic stem cell transplantation. Bone Marrow Transplant. 2001;27:893-898. doi:10.1038/sj.bmt.1703015\u003c/li\u003e\n\u003cli\u003eN\u0026uuml;rnberger W, Willers R, Burdach S, G\u0026ouml;bel U. Risk factors for capillary leakage syndrome after bone marrow transplantation. Ann Hematol. 1997;74:221-224. doi:10.1007/s002770050288\u003c/li\u003e\n\u003cli\u003eCahill RA, Spitzer TR, Mazumder A. Marrow engraftment and clinical manifestations of capillary leak syndrome. Bone Marrow Transplant. 1996;18:177-184.\u003c/li\u003e\n\u003cli\u003eSpitzer TR. Engraftment syndrome: double-edged sword of hematopoietic cell transplants. Bone Marrow Transplant. 2015;50:469-475. doi:10.1038/bmt.2014.296\u003c/li\u003e\n\u003cli\u003eChang L, Frame D, Braun T, et al. Engraftment syndrome after allogeneic hematopoietic cell transplantation predicts poor outcomes. Biol Blood Marrow Transplant. 2014;20:1407-1417. doi:10.1016/j.bbmt.2014.05.022\u003c/li\u003e\n\u003cli\u003eSingh I, Mikita G, Green D, Risquez C, Sanders A. Pulmonary extra-medullary hematopoiesis and pulmonary hypertension from underlying polycythemia vera: a case series. Pulm Circ. 2017;7:261-267. Published 2017 Mar 10. doi:10.1177/2045893217702064\u003c/li\u003e\n\u003cli\u003eYang M, Covington MF, Nguyen BD, Johnson GB, Mesa RA, Roarke MC. \u003csup\u003e99m\u003c/sup\u003eTc-Sulfur Colloid Bone Marrow Scintigraphy in Diagnosis of Diffuse Pulmonary Extramedullary Hematopoiesis Secondary to Myelofibrosis. J Nucl Med Technol. 2018;46:368-372. doi:10.2967/jnmt.118.210534 \u003c/li\u003e\n\u003cli\u003eGupta R, Jamal F, Yang D, et al. Pulmonary hypertension is associated with increased nonrelapse mortality after allogeneic hematopoietic cell transplantation for myelofibrosis. Bone Marrow Transplant. 2020;55:877-883. doi:10.1038/s41409-019-0741-8\u003c/li\u003e\n\u003cli\u003eSingh H, Kurman JS, Jani CT, Rao N, Benn BS. An 80-year-old woman with myelofibrosis and diffuse mosaic attenuation on chest computed tomography. Respir Med Case Rep. 2022;38:101705. Published 2022 Jul 11. doi:10.1016/j.rmcr.2022.101705\u003c/li\u003e\n\u003cli\u003eWyatt SH, Fishman EK. Diffuse pulmonary extramedullary hematopoiesis in a patient with myelofibrosis: CT findings. J Comput Assist Tomogr. 1994;18:815-817. doi:10.1097/00004728-199409000-00023\u003c/li\u003e\n\u003cli\u003eChunduri S, Gaitonde S, Ciurea SO, Hoffman R, Rondelli D. Pulmonary extramedullary hematopoiesis in patients with myelofibrosis undergoing allogeneic stem cell transplantation. Haematologica. 2008;93:1593-1595. doi:10.3324/haematol.13203\u003c/li\u003e\n\u003cli\u003eEnokida K, Tomomatsu K, Okada N, et al. Transudative Pleural Effusion Associated with Extramedullary Hematopoiesis. Intern Med. 2021;60:449-452. doi:10.2169/internalmedicine.4668-20\u003c/li\u003e\n\u003cli\u003eAli H, Tsai NC, Synold T, et al. Peritransplantation ruxolitinib administration is safe and effective in patients with myelofibrosis: a pilot open-label study. Blood Adv. 2022;6:1444-1453. doi:10.1182/bloodadvances.2021005035\u003c/li\u003e\n\u003cli\u003eMaccaferri M, Leonardi G, Marasca R, et al. Ruxolitinib for pulmonary extramedullary hematopoiesis in myelofibrosis. Leuk Lymphoma. 2014;55:2207-2208. doi:10.3109/10428194.2013.873538 \u003c/li\u003e\n\u003cli\u003eFujimoto A, Hamaguchi S, Suzuki R. Case of Pulmonary Extramedullary Hematopoiesis Responding to Ruxolitinib. Leuk Res Rep. 2022;17:100290. Published 2022 Feb 7. doi:10.1016/j.lrr.2022.100290\u003c/li\u003e\n\u003cli\u003eTabarroki A, Lindner DJ, Visconte V, et al. Ruxolitinib leads to improvement of pulmonary hypertension in patients with myelofibrosis. Leukemia. 2014;28:1486-1493. doi:10.1038/leu.2014.5\u003c/li\u003e\n\u003c/ol\u003e"}],"fulltextSource":"","fullText":"","funders":[],"hasAdminPriorityOnWorkflow":false,"hasManuscriptDocX":true,"hasOptedInToPreprint":true,"hasPassedJournalQc":"","hasAnyPriority":false,"hideJournal":false,"highlight":"","institution":"","isAcceptedByJournal":true,"isAuthorSuppliedPdf":false,"isDeskRejected":"","isHiddenFromSearch":false,"isInQc":false,"isInWorkflow":false,"isPdf":false,"isPdfUpToDate":true,"isWithdrawnOrRetracted":false,"journal":{"display":true,"email":"[email protected]","identity":"bone-marrow-transplantation","isNatureJournal":false,"hasQc":false,"allowDirectSubmit":false,"externalIdentity":"bmt","sideBox":"Learn more about [Bone Marrow Transplantation](http://www.nature.com/bmt/)","snPcode":"41409","submissionUrl":"https://mts-bmt.nature.com/cgi-bin/main.plex","title":"Bone Marrow Transplantation","twitterHandle":"@bmtjournal","acdcEnabled":true,"dfaEnabled":true,"editorialSystem":"ejp","reportingPortfolio":"Nature AJ","inReviewEnabled":true,"inReviewRevisionsEnabled":false},"keywords":"Myelofibrosis, allogeneic stem cell transplant, pulmonary infiltrates, pulmonary hypertension, engraftment syndrome, extramedullary hematopoiesis ","lastPublishedDoi":"10.21203/rs.3.rs-6568124/v1","lastPublishedDoiUrl":"https://doi.org/10.21203/rs.3.rs-6568124/v1","license":{"name":"CC BY 4.0","url":"https://creativecommons.org/licenses/by/4.0/"},"manuscriptAbstract":"\u003cp\u003eAllogeneic hematopoietic cell transplantation (alloHCT) remains the only potentially curative treatment for both primary and secondary myelofibrosis (MF). However, outcomes are often complicated by the presence of cardiopulmonary comorbidities common in this patient population, contributing to elevated non-relapse mortality (NRM). In this study, we characterize a distinct clinical entity\u0026mdash;pulmonary manifestations during neutrophil engraftment\u0026mdash;marked by pulmonary infiltrates and respiratory compromise in patients undergoing alloHCT for MF. Eighteen of 83 patients (22%) developed these pulmonary complications, with radiologic findings including ground-glass opacities, consolidations, and pulmonary nodules. Notably, only one-third of these patients exhibited additional features typically associated with classical engraftment syndrome. Pulmonary arterial hypertension (PAH) was significantly associated with the development of these complications (odds ratio 3.68; 95% CI: 1.13\u0026ndash;12; P\u0026thinsp;=\u0026thinsp;0.04), whereas no correlation was found with pre-transplant pulmonary function testing or imaging. Hypoxemia was observed in 15 of the 18 affected patients. Despite the severity\u0026mdash;44% requiring intensive care and 40% necessitating mechanical ventilation\u0026mdash;all patients responded favorably to corticosteroids and supportive care. Importantly, the presence of pulmonary complications during engraftment did not negatively affect overall survival or NRM.\u003c/p\u003e","manuscriptTitle":"Pulmonary manifestations during neutrophil engraftment in recipients of allogeneic hematopoietic cell transplantation for myelofibrosis","msid":"","msnumber":"","nonDraftVersions":[{"code":1,"date":"2025-05-09 14:27:18","doi":"10.21203/rs.3.rs-6568124/v1","editorialEvents":[{"type":"communityComments","content":0},{"type":"decision","content":"revise","date":"2025-06-20T08:29:03+00:00","index":"","fulltext":""},{"type":"editorInvitedReview","content":"This content is not available.","date":"2025-06-13T16:53:22+00:00","index":2,"fulltext":"This content is not available."},{"type":"reviewerAgreed","content":"This content is not available.","date":"2025-06-12T17:03:57+00:00","index":2,"fulltext":"This content is not available."},{"type":"editorInvitedReview","content":"This content is not available.","date":"2025-05-22T14:08:50+00:00","index":1,"fulltext":"This content is not available."},{"type":"reviewerAgreed","content":"This content is not available.","date":"2025-05-09T11:16:55+00:00","index":1,"fulltext":"This content is not available."},{"type":"reviewersInvited","content":"","date":"2025-05-06T06:50:16+00:00","index":"","fulltext":""},{"type":"checksComplete","content":"","date":"2025-05-02T08:39:20+00:00","index":"","fulltext":""},{"type":"submitted","content":"Bone Marrow Transplantation","date":"2025-05-01T21:08:53+00:00","index":"","fulltext":""},{"type":"checksFailed","content":"","date":"2025-05-01T09:43:06+00:00","index":"","fulltext":""},{"type":"editorAssigned","content":"","date":"2025-04-30T22:45:23+00:00","index":"","fulltext":""}],"status":"published","journal":{"display":true,"email":"[email protected]","identity":"bone-marrow-transplantation","isNatureJournal":false,"hasQc":false,"allowDirectSubmit":false,"externalIdentity":"bmt","sideBox":"Learn more about [Bone Marrow Transplantation](http://www.nature.com/bmt/)","snPcode":"41409","submissionUrl":"https://mts-bmt.nature.com/cgi-bin/main.plex","title":"Bone Marrow Transplantation","twitterHandle":"@bmtjournal","acdcEnabled":true,"dfaEnabled":true,"editorialSystem":"ejp","reportingPortfolio":"Nature AJ","inReviewEnabled":true,"inReviewRevisionsEnabled":false}}],"origin":"","ownerIdentity":"4afc9c4a-8991-49de-b6e2-351410a8dd14","owner":[],"postedDate":"May 9th, 2025","published":true,"recentEditorialEvents":[],"rejectedJournal":[],"revision":"","amendment":"","status":"published-in-journal","subjectAreas":[{"id":48115833,"name":"Biological sciences/Stem cells/Haematopoietic stem cells"},{"id":48115834,"name":"Health sciences/Risk factors"}],"tags":[],"updatedAt":"2025-09-25T07:10:52+00:00","versionOfRecord":{"articleIdentity":"rs-6568124","link":"https://doi.org/10.1038/s41409-025-02724-w","journal":{"identity":"bone-marrow-transplantation","isVorOnly":false,"title":"Bone Marrow Transplantation"},"publishedOn":"2025-09-24 04:00:00","publishedOnDateReadable":"September 24th, 2025"},"versionCreatedAt":"2025-05-09 14:27:18","video":"","vorDoi":"10.1038/s41409-025-02724-w","vorDoiUrl":"https://doi.org/10.1038/s41409-025-02724-w","workflowStages":[]},"version":"v1","identity":"rs-6568124","journalConfig":"researchsquare"},"__N_SSP":true},"page":"/article/[identity]/[[...version]]","query":{"redirect":"/article/rs-6568124","identity":"rs-6568124","version":["v1"]},"buildId":"8U1c8b4HqxoKbykW_rLl7","isFallback":false,"isExperimentalCompile":false,"dynamicIds":[84888],"gssp":true,"scriptLoader":[]}